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Chronic Traumatic Encephalopathy-Integration of Canonical 
Traumatic Brain Injury Secondary Injury Mechanisms with Tau 
Pathology
Jacqueline R. Kulbe and Edward D. Hall
Spinal Cord & Brain Injury Research Center and Department of Neuroscience, University of 
Kentucky College of Medicine
Abstract
In recent years, a new neurodegenerative tauopathy labeled Chronic Traumatic Encephalopathy 
(CTE), has been identified that is believed to be primarily a sequela of repeated mild traumatic 
brain injury (TBI), often referred to as concussion, that occurs in athletes participating in contact 
sports (e.g. boxing, football, football, rugby, soccer, ice hockey) or in military combatants, 
especially after blast-induced injuries. Since the identification of CTE, and its neuropathological 
finding of deposits of hyperphosphorylated tau protein, mechanistic attention has been on lumping 
the disorder together with various other non-traumatic neurodegenerative tauopathies. Indeed, 
brains from suspected CTE cases that have come to autopsy have been confirmed to have deposits 
of hyperphosphorylated tau in locations that make its anatomical distribution distinct for other 
tauopathies. The fact that these individuals experienced repetitive TBI episodes during their 
athletic or military careers suggests that the secondary injury mechanisms that have been 
extensively characterized in acute TBI preclinical models, and in TBI patients, including 
glutamate excitotoxicity, intracellular calcium overload, mitochondrial dysfunction, free radical-
induced oxidative damage and neuroinflammation, may contribute to the brain damage associated 
with CTE. Thus, the current review begins with an in depth analysis of what is known about the 
tau protein and its functions and dysfunctions followed by a discussion of the major TBI 
secondary injury mechanisms, and how the latter have been shown to contribute to tau pathology. 
The value of this review is that it might lead to improved neuroprotective strategies for either 
prophylactically attenuating the development of CTE or slowing its progression.
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1. Introduction
Chronic traumatic encephalopathy (CTE) is classified as a neurodegenerative tauophathy 
(McKee et al., 2016). In addition to CTE several other tauopathies exist including 
Alzheimer's disease (AD), frontotemporal dementia (FTD), progressive supra nuclear palsy 
(PSP), corticobasal degeneration, Pick's disease, and argyrophilic grain disease (Lee and 
Leugers, 2012). One defining characteristic of tauopathies is hyperphosphorylation of the 
protein tau. Once hyperphosphorylated, tau assumes a tightly folded confirmation, 
increasing susceptibility to aggregation, conformational change, filament assembly, 
polymerization into paired helical filaments, and bundling of paired helical filaments into 
neurofibrillary tangles and neuropil threads (Mietelska-Porowska et al., 2014).
Clinically, CTE is characterized by cognitive, behavioral, and/or mood dysfunction, with the 
possible accompaniment of motor symptoms (Montenigro et al., 2014). Unfortunately, the 
current incidence and prevalence of CTE is unknown (Kiernan et al., 2015) because 
although CTE can be suspected clinically, a definitive diagnosis can only be made post-
mortem (McKee et al., 2016). Recently, a consensus meeting was held to define the 
neuropathological criteria of CTE, and concluded that a CTE diagnosis should be based 
upon identification of an irregular pattern of abnormally hyperphosphorylated tau 
accumulations in astrocytes and neurons located around small blood vessels and at the 
depths of cortical sulci (McKee et al., 2016). Additional non-specific, but supportive features 
of CTE, include hippocampal tangles, neurofibrillary tangles in the subcortical nuclei, and 
TAR DNA-binding protein 43 (TDP-43) reactivity in the temporal cortex, hippocampus and 
amygdala (McKee et al., 2016). However, in reaching the consensus, definition other 
neuropathologic characteristics of CTE were not addressed including gliosis, inflammation, 
hemosiderin deposition, and the presence of comorbid pathologies such as Aβ and α-
synuclein deposition (McKee et al., 2016). Although the neuropathologic criteria for CTE 
have now been defined, identification of CTE as a unique entity remains controversial for 
several reasons including reliance on retrospective case reports subject to selection bias for 
identification of cases (Maroon et al., 2015), as well a lack of prospective and epidemiologic 
studies (McCrory et al., 2013). Indeed, the clinical diagnostic criteria of CTE vs. other 
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neurodegenerative disorders (e.g. AD) for which the history of one or more traumatic brain 
injuries is an established risk factor is still being intensely debated.
Nevertheless, to date, CTE pathology has only been identified in individuals with a history 
of traumatic brain injury (TBI) (McKee et al., 2016). CTE pathology has been observed in 
the brains of military personnel who have sustained blast injuries, and in athletes who 
participate in sports where the risk of sustaining repetitive head injuries is high including 
boxing, football, soccer, hockey and rugby (Goldstein et al., 2012; Kiernan et al., 2015; 
McKee et al., 2009; McKee and Robinson, 2014; McKee et al., 2013; Omalu et al., 2011b; 
Omalu et al., 2006; Omalu et al., 2005). Although there are several tauopathies, the 
pathoanatomic location of tau deposition in CTE makes it distinct from the others (Kiernan 
et al., 2015; McKee et al., 2016). However, the neuronal tau found in CTE does share a 
similar profile in regard to isoform ratio and phosphorylation state as the tau in AD (Kiernan 
et al., 2015; McKee et al., 2014; Schmidt et al., 2001). CTE and AD share other similarities; 
brain injury also increases the risk of developing AD (Guo et al., 2000; Nemetz et al., 1999; 
Plassman et al., 2000). In fact both pathologic tau (Ikonomovic et al., 2004; Johnson et al., 
2012; Uryu et al., 2007) and Aβ deposition (Johnson et al., 2012; Reynolds et al., 2005; 
Reynolds et al., 2006) are seen following a single severe TBI.
Although advancements have been made in defining the core neuropathological features of 
CTE, much about CTE is still unknown. Similar to brain injury itself, CTE is heterogeneous 
both in its supporting neuropathological features (McKee et al., 2016) and in its clinical 
presentation. Clinically, CTE is suspected of having at least two subtypes, a younger onset 
subtype predominated by behavior and mood symptoms but with minimal cognitive or motor 
impairment, and an older onset subtype characterized by cognitive impairment and motor 
dysfunction (Stern et al., 2013). However, up to four clinical subtypes have been proposed 
(Montenigro et al., 2014).
The pathophysiologic processes which lead to the development of CTE, the main 
characteristic of which is pathologic tau deposition, are not well understood. Although 
repetitive TBI has been singled out as a major etiologic factor in CTE and brain injury is 
considered necessary for its development (McKee et al., 2016), individuals who have 
experienced repetitive TBI do not always go on to develop CTE (Hazrati et al., 2013; McKee 
et al., 2013; Omalu et al., 2011a). Additional factors hypothesized to contribute to CTE 
include environment, genetics and injury characteristics, e.g. age at injury, type and severity 
of injury, number of hits, duration between injuries, etc. (Ojo et al., 2016) Although animal 
models are being utilized to further characterize CTE and repetitive TBI, many have failed to 
recapitulate the tau pathology seen in CTE or have required the use of transgenic mice 
already predisposed to develop tau pathology (Ojo et al., 2016). Therefore, there is much 
still to be elucidated regarding the progression of CTE following injury. However, despite 
the paucity of information regarding how CTE tau pathology progresses over time, the tau 
protein itself and processes that contribute to its dysfunction have been well characterized in 
the literature, thanks in large part to AD, FTD and TBI models in which tauopathy is 
a.commonly occurring pathology.
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In this review, which focuses on CTE, we attempt to integrate what is known about 
canonical post-traumatic neurodegenerative processes and the tau protein in order to identify 
mechanisms which could possibly lead to, or contribute to, chronic tau dysfunction 
following TBI that might serve as pharmacological neuroprotective targets. We have chosen 
to direct our attention to CTE because, by definition it is associated with the previous 
occurrence of repetitive, and possibly singular TBI even though, a history of TBI is known 
to be a risk factor for other neurodegenerative disorders that are involve the same secondary 
post-TBI degenerative mechanisms. Thus, throughout the rest of this review, we consistently 
mention what is known about the interaction of post-TBI secondary injury processes such as 
mitochondrial dysfunction oxidative stress, intracellular calcium overload, etc., with the 
pathogenesis of other neurodegenerative disorders as AD, that involve tauopathies that 
appear to be somewhat pathologically distinct from CTE. While this review is mainly 
directed at CTE, our literature review has revealed a rich interaction between acute post-TBI 
secondary injury mechanisms and tauopathy development in general.
2. The Tau Protein – Functions and Dysfunctions
2.1 Functions
There are several detailed reviews that cover structure, function, and post-translational 
modification of the tau protein (Fontaine et al., 2015; Lee and Leugers, 2012; Morris et al., 
2011). Tau is encoded for by the MAPT gene found on chromosome 17, a gene that is 
mutated in several tauopathies including FTD (Ferrari et al., 2011) and PSP (Im et al., 2015). 
In humans, alternative splicing generates six isoforms of tau containing either three (3R) or 
four (4R) microtubule binding repeats (Goedert and Jakes, 1990), leading to formation of 
isoforms with differing characteristics (Lee and Leugers, 2012). Additional heterogeneity 
exists in the n-terminal region as well (Goedert and Jakes, 1990). As stated previously, the 
neuronal tau of CTE has a similar isoform ratio and phosphorylation state as the tau of AD 
(Kiernan et al., 2015; McKee et al., 2014; Schmidt et al., 2001). AD is reported to have a 2:1 
ratio of 4R:3R tau (Chen et al., 2010b; Conrad et al., 2007; Ginsberg et al., 2006), a shift 
from the equal 4R:3R ratio found in healthy adult brains (Goedert and Jakes, 1990; Kosik et 
al., 1989).
The most well-known function of tau is its ability to bind microtubules, which promotes 
microtubule assembly and stabilization (Fontaine et al., 2015; Lee and Leugers, 2012; 
Morris et al., 2011). However, tau has several other functions, including axonal transport 
(Cuchillo-Ibanez et al., 2008; Lee and Leugers, 2012; Morris et al., 2011), regulation of 
actin and neurite outgrowth (Lee and Leugers, 2012; Morris et al., 2011), and regulation of 
signaling pathways (Morris et al., 2011). Tau can associate with heat shock proteins, 
chaperone proteins involved in the tau degradation pathway (Fontaine et al., 2015; Lee and 
Leugers, 2012), and although tau is primarily found associated with the cytoskeleton of 
axons, it can also localize to the nucleus, as well as interact with the plasma membrane and 
post-synaptic density (Fontaine et al., 2015; Lee and Leugers, 2012; Morris et al., 2011).
The binding of tau to microtubules can be regulated by the tau phosphorylation state, and 
phosphorylation of tau within the microtubule binding sites decreases the ability of tau to 
bind microtubules (Fontaine et al., 2015). Similarly, several of the tau mutations utilized in 
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transgenic tau mice, such as P301L and P301S, function to decrease binding of tau to 
microtubules and can lead to decreases in microtubule assembly (Fontaine et al., 2015; 
Hasegawa et al., 1998; Iovino et al., 2014). Several protein kinases and phosphatases 
regulate tau phosphorylation, and thus its ability to interact with microtubules (Fontaine et 
al., 2015; Martin et al., 2013; Morris et al., 2011).
2.2 Dysfunctions
One characteristic feature of tauopathies, such as CTE and AD, is tau hyperphosphorylation, 
where phosphorylation of tau at specific residues occurs as an ordered process, leading to 
tau aggregation (Alonso et al., 2001; Fontaine et al., 2015; Jeganathan et al., 2008; Morris et 
al., 2011) and oligomer formation (Tepper et al., 2014). In addition to tauopathies, TBI is 
also capable of inducing tau hyperphosphorylation (Ikonomovic et al., 2004; Uryu et al., 
2007; Yang et al., 2016).
In addition to phosphorylation other post-translational modifications to tau occur such as 
acetylation, glycosylation, sumolyation, ubiquitination, polyamination, oxidation, nitration, 
isomerization and truncation (Fontaine et al., 2015; Morris et al., 2011). Many of these post-
translational modifications have been implicated in the formation of pathologic tau. For 
example, oxidation of tau induces cross-linkages and aggregation (Reynolds et al., 2005) and 
nitration of tau decreases microtubule binding and assembly (Reynolds et al., 2005). 
Isomerization of pThr231 tau to the cis isoform attenuates tau dephosphorylation, decreases 
microtubule binding, and promotes aggregation (Wang and Zhang, 2015), and proteolytic 
cleavage of tau by calpain or caspase (Liu et al., 2011) can result in formation of truncated 
tau species which are prone to aggregation (Fontaine et al., 2015).
The mechanisms regarding tau toxicity in neurodegenerative disease remain controversial 
(Morris et al., 2011), with both loss of function and gain of function theories being proposed 
(Trojanowski and Lee, 2005). However, although hyperphosphorylated tau results in 
decreased binding of tau to microtubules, several studies indicate that knock-down of tau 
results in normal behavioral phenotypes, synaptic transmission and microtubule stability, 
without compensatory increases in other microtubule-binding proteins, such as MAP1 or 
MAP2, suggesting that tau toxicity may not be a direct result of loss of function (Morris et 
al., 2011). Rather, the toxicity associated with pathologic tau may in part be due to tau 
mislocalization and/or dysfunctional axonal transport. The majority of tau is localized to 
axons (Morris et al., 2011); however, tau hyperphosphorylation results in redistribution of 
tau from the axon to the somatodendritic compartment, an effect which is sufficient to 
impair synaptic function (Hoover et al., 2010), and several studies have shown that 
pathologic tau isoforms impair fast axonal transport (Lee and Leugers, 2012).
Evidence has also accumulated suggesting that tau oligomers, i.e. pre-filamentous tau 
aggregates, are more toxic than filamentous or monomeric tau (Spires-Jones et al., 2011). 
For example, injection of human tau oligomers into mouse brains results in impaired 
memory consolidation, as well as synaptic and mitochondrial dysfunction, whereas 
administration of tau monomers or fibrils does not (Lasagna-Reeves et al., 2011), while 
repression of human tau in transgenic mice results in attenuation of neuronal loss and 
cognitive impairment despite continued increases in neurofibrillary tangle formation 
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(Santacruz et al., 2005). Similarly, in a drosophila model of tauopathy, neurodegeneration 
can still be seen in the absence of neurofibrillary tangle formation (Wittmann et al., 2001). 
Interestingly, It has been hypothesized that one reason oligomeric tau is able to accumulate 
in tauopathies is due to the fact that both oligomeric tau and cleaved forms of tau, which 
have an increased propensity for aggregation compared to full-length tau, are preferentially 
degraded via autophagy (Chesser et al., 2013), a pathway reported to be defective in 
tauopathies (Piras et al., 2016) and TBI (Sarkar et al., 2014). Although proteasome 
dysfunction, the mechanism which preferentially degrades monomeric tau, has also been 
reported to occur following TBI due to mechanisms such as oxidative stress (Bader and 
Grune, 2006; Weih et al., 2001; Yao et al., 2008), monomeric full-length tau has a decreased 
propensity to aggregate compared to cleaved tau (Chesser et al., 2013) and is less toxic than 
oligomeric tau (Spires-Jones et al., 2011).
Tau is considered to have prion-like properties (Alonso et al., 2016; Medina and Avila, 
2014), which likely contribute to intracellular, intraregional, and trans-synaptic spread of 
pathologic tau (Liu et al., 2012; Medina and Avila, 2014). Tau can be secreted from neurons 
in its naked form or within exosomes or membrane vesicles (Chai et al., 2012; Medina and 
Avila, 2014; Saman et al., 2012; Simon et al., 2012). In healthy neurons the release of tau is 
induced by neuronal activity, however, neuronal activity is altered following TBI (Carron et 
al., 2016) and in tauopathy brains (Pooler et al., 2013), likely resulting in abnormal tau 
release (Pooler et al., 2013). Additionally, both c-terminal proteolytic cleavage of tau and tau 
overexpression are capable of enhancing tau secretion (Medina and Avila, 2014; Plouffe et 
al., 2012; Simon et al., 2012). In-vitro, extracellular tau is known to be toxic (Gomez-Ramos 
et al., 2006; Medina and Avila, 2014), through a mechanism which may involve increases in 
intracellular calcium levels via tau stimulation of muscarinic receptors (Gomez-Ramos et al., 
2008), and in further support of the toxic oligomeric theory, only extracellular tau 
aggregates, not tau monomers, are taken up by cells (Alonso et al., 2016; Frost et al., 2009; 
Wu et al., 2013). Once tau is secreted, the extracellular tau has the ability to enhance tau 
pathology. For example, transplanting TBI induced tau oligomers into naive brains of hTau 
transgenic mice results in oligomeric spread of tau and accelerated cognitive impairment 
(Gerson et al., 2016), secreted tau fibrils are capable of inducing transcellular misfolding and 
tau aggregation (Kfoury et al., 2012), and hyperphosphorylated tau is capable of forming 
filaments and tangles with non-phosphorylated tau (Alonso et al., 1996). Therefore, it is 
possible that in non-familial tauopathies, such as CTE, an initial event, such as repetitive 
TBI, triggers a misfolding cascade which can then be transmitted in a prion-like manner 
(Morales et al., 2015).
3. Traumatic Brain Injury - Pathophysiological Mechanisms
Although the specific mechanisms by which repetitive TBI can lead to CTE or by which a 
single severe TBI can lead to AD are still being elucidated, much of the pathology that 
occurs in tauopathies is paralleled in TBI. TBIs range from mild to severe, with at least 2.5 
million TBIs occurring in the United States annually (Faul M, 2010), the majority of which 
are classified as mild (Holm et al., 2005). However, these numbers are underestimates 
because mild TBIs often go unreported, especially in sports and military communities 
(Jordan, 2013; Marion et al., 2011), populations which are at additional risk for sustaining 
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repeat injuries. In fact, it is estimated that sports-related TBIs alone occur at a rate of 3.8 
million annually (Langlois et al., 2006).
3.1 Primary Injury Mechanisms
TBI consists of a primary injury followed by a secondary injury cascade. The primary injury 
occurs immediately and is caused by external forces, such as a direct impact, rapid 
acceleration/deceleration, or blast a wave. Primary injury can result in contusion, 
hemorrhage, ischemia, shearing and straining of axons and blood vessels, and diffuse axonal 
injury from the mechanical insult (Maas et al., 2008; McAllister, 2011; Weber, 2012). Of 
important relevance to CTE, which consists of tau pathology located at the depths of cortical 
sulci and around blood vessels, are deceleration/acceleration and blast forces (McKee et al., 
2016). Deceleration/acceleration forces are particularly damaging to long white matter tracts 
and the grey-white matter junctions of the cerebral cortex (McAllister, 2011), and blast 
injury has been reported to damage perivascular neural tissue due to transmission of pressure 
waves throughout the cerebral vasculature (McAllister, 2011).
3.2 Secondary Injury Mechanisms
Cellular strain and deformation caused by the primary injury results in membrane 
depolarization, mechanoporation of membranes, ionic imbalances, and neurotransmitter 
release, resulting in initiation of the secondary injury cascade, a process which occurs hours 
to weeks following injury (Maas et al., 2008; McAllister, 2011), and is heavily influenced by 
alterations in calcium homeostasis (Weber, 2012).
3.2.1 Intracellular Calcium Overload, Oxidative Damage and Mitochondrial 
Dysfunction—Activation of calcium channels by high levels of extracellular glutamate 
following injury, along with activation of voltage-gated calcium channels and membrane 
leakage lead to large increases in intracellular calcium (Weber, 2012). As essential regulators 
or calcium homeostasis (Rizzuto et al., 2000; Rizzuto et al., 1999) mitochondria buffer the 
increases in intracellular calcium following TBI (Lifshitz et al., 2003; Xiong et al., 1997). 
Increases in mitochondrial calcium lead to decreased respiration and increased generation of 
reactive oxygen and nitrogen species (ROS/RNS) (Fiskum, 2000; Sullivan et al., 2005). 
Following TBI, as the electron transport chain becomes impaired, single electrons leak from 
complex I, generating superoxide radicals (O2•-), which rapidly react the nitric oxide (NO•) 
generated by calcium activated mitochondrial nitric oxide synthase (mtNOS), forming 
peroxynitrite (PN) anion (ONOO-) (Bringold et al., 2000; Radi et al., 2002). Protonation of 
ONOO- results in peroxynitrious acid (ONOOH) which decomposes into nitrogen dioxide 
(NO•2) and hydroxyl (OH•) radicals. Alternatively, ONOO- can react with carbon dioxide to 
form nitrosoperoxocarbonate (ONOOCO2-) which decomposes into the radicals NO•2 and 
(CO•-3) (Bains and Hall, 2012; Hall et al., 2010). PN is demonstratively increased following 
TBI (Deng et al., 2007; Hall et al., 2004; Hall et al., 2012; Singh et al., 2007) and because of 
its unique diffusion radius, mitochondrial derived PN is capable of damaging multiple 
cellular structures (Hall et al., 2010).
The highly reactive PN-derived radicals, NO•2, OH•, CO•-3, initiate lipid peroxidation (LP) 
of polyunsaturated fatty acids, such as arachidonic acid, which are highly enriched in 
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neurons and cellular and organelle membranes, forming lipid peroxyl radicals (Bains and 
Hall, 2012; Hall et al., 2010). LP propagates throughout the membrane as lipid peroxyl 
radicals react with adjacent polyunsaturated acids, and although lipid peroxidation is 
considered to be a self-propagating process, it is also catalyzed by the presence of iron, 
particularly in the acidic tissues of TBI (Hall et al., 2010). Following TBI, decreases in pH 
cause iron to be released from the iron storage proteins, ferritin and transferritin, and 
additional iron is released from the hemoglobin deposited during hemorrhages and 
microbleeds (Hall et al., 2010). Therefore, similar to tau deposition in CTE, iron-catalyzed 
LP may be enhanced near the vasculature following TBI. LP terminates with formation of 
neurotoxic aldehydes, such as 4-hydroxynonenal (4-HNE) and 2-propenal (acrolein). Both 
LP and its derivatives, 4-HNE and acrolein, are well known to be increased following TBI 
(Bayir et al., 2007; Hall et al., 2004; Mustafa et al., 2010; Mustafa et al., 2011; Singh et al., 
2013) (Cebak et al., 2016; Hill et al., Submitted).
The neurotoxic aldehydes, 4-HNE and acrolein, covalently bind proteins via the amino acids 
lysine, histidine, or cysteine, resulting in enzyme inhibition and protein dysfunction (Hall et 
al., 2010; Petersen and Doorn, 2004; Stevens and Maier, 2008). In addition to protein 
dysfunction, neurotoxic aldehydes, ROS/RNS and lipid peroxyl radicals are capable of 
inducing DNA damage to both nuclear and mitochondrial DNA (Dalleau et al., 2013; Hall et 
al., 2010). As a major site of PN formation, mitochondria are particularly susceptible to 
attack by LP-derived neurotoxic aldehydes. Binding of 4-HNE and acrolein to mitochondria 
results in extensive mitochondrial dysfunction through impairment of mitochondrial 
respiration and enhanced generation of ROS/RNS (Singh et al., 2013; Vaishnav et al., 2010) 
(Cebak et al., 2016; Hill et al., Submitted; Miller et al., 2013; Picklo et al., 1999; Picklo and 
Montine, 2001). Following TBI, the mitochondrial dysfunction induced by LP-derived 
neurotoxic aldehydes and increased intra-mitochondrial calcium concentrations leads to 
formation of the mitochondrial permeability transition pore (mPTP) (Bringold et al., 2000; 
Hansson et al., 2008; Sullivan et al., 2005). Opening of the mPTP results in collapse of the 
mitochondrial membrane potential, loss of ATP production, mitochondrial swelling, rupture 
of the outer mitochondrial membrane and release of calcium and cytochrome c into the 
cytosol (Galluzzi et al., 2009; Sullivan et al., 2005).
3.2.2 Calcium-Mediated Proteolytic Degradation—Extrusion of calcium back into 
the cytosol leads to neurodegeneration, necrosis, and activation of the calcium-dependent 
cysteine protease, calpain, which is capable of breaking down a variety of cytoskeletal 
proteins including MAP2, spectrin and tau (Galluzzi et al., 2009; Kampfl et al., 1997; 
Sullivan et al., 2005; Wang, 2000). In fact, calpain-cleaved αII-spectrin breakdown products 
are frequently used to assess post-TBI axonal damage and neuroprotection following TBI 
(Bains et al., 2013; Deng-Bryant et al., 2008; Deng et al., 2007; Mbye et al., 2009; Miller et 
al., 2014; Mustafa et al., 2011; Saatman et al., 1996). Similarly, mitochondrial release of 
cytochrome c leads to activation of the protease caspase-3 and induction of apoptosis 
(Galluzzi et al., 2009; Sullivan et al., 2005; Wang, 2000).
One effect of cytoskeletal degradation following TBI is impairment of axonal transport. 
Following injury, axonal transport of amyloid precursor protein (APP), the precursor to Aβ, 
a pathologic protein found in the tauopathy, AD, and some cases of CTE, is impaired and 
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results in accumulations of APP in axonal varicosities and bulbs of damaged neurons; as 
such, the accumulation of APP following TBI is often used as a marker for traumatic axonal 
injury (Chauhan, 2014). In addition to cytoskeletal degradation, protein accumulation 
following TBI can also occur due to proteasomal dysfunction (Yao et al., 2008). In 
particular, the proteasome is responsible for the degradation of oxidatively damaged 
proteins, however, it is also subject to oxidative stress-induced impairment itself (Bader and 
Grune, 2006; Weih et al., 2001; Yao et al., 2008). In addition to protein accumulation 
following injury, impairment of axonal transport also leads to somatodendritic accumulation 
of organelles, such as the mitochondria (Kilinc et al., 2008), although, impairment of 
mitochondrial dynamics following TBI is complex and includes additional processes such as 
alterations in fission and fusion (Fischer et al., 2016).
Following injury, the endoplasmic reticulum (ER) also functions to regulate calcium 
homeostasis (Weber, 2012). Increases in ER stress are reported to occur in both single 
(Begum et al., 2014; Krajewska et al., 2011; Larner et al., 2004; Logsdon et al., 2014) and 
repetitive TBI (Lucke-Wold et al., 2016). In fact, calcium release from the ER has been 
hypothesized to be toxic to neurons and white matter tracts (Weber, 2012). In addition to 
regulation of intracellular calcium stores, the ER is involved in protein folding and quality 
control of misfolded proteins and protein aggregates through a process termed, the unfolded 
protein response (UPR) (Hoozemans and Scheper, 2012). Therefore, in addition to calcium-
induced pathology, ER stress can also lead to several additional aspects of cellular 
dysfunction, including inhibition of protein synthesis (Doutheil et al., 1997), apoptosis 
(Nakagawa et al., 2000), accumulation of protein aggregates (Hoozemans and Scheper, 
2012), and activation of the tau kinase, GSK-3β (Song et al., 2002).
3.2.3 Neuroinflammation—Another important contributory factor to the pathology that 
occurs following TBI is inflammation. Inflammation has been observed acutely following 
TBI in both severe and mild injury, an effect which is amplified in mild TBI by repeated 
injury (Collins-Praino and Corrigan, 2016). Following injury, resident immune cells, such as 
astrocytes and microglia, are activated by damaged tissue and cellular debris (Collins-Praino 
and Corrigan, 2016; Karve et al., 2016), but can also be activated by other mechanisms such 
as ROS/RNS (Collins-Praino and Corrigan, 2016). Additionally, peripheral immune cells are 
recruited to the site of injury (Collins-Praino and Corrigan, 2016; Karve et al., 2016). 
Immune cells are capable of releasing both pro-inflammatory and pro-survival cytokines and 
chemokines; therefore, they are capable of serving both destructive and reparative roles 
following injury (Collins-Praino and Corrigan, 2016; Karve et al., 2016). For example, the 
microglial phenotype M1 is neurotoxic, while the microglial phenotype M2 is 
neuroprotective (Karve et al., 2016). Chronic microglial activation has been observed 
following both human and experimental TBI and has been linked to chronic 
neurodegeneration (Faden and Loane, 2015). In fact, the neurotoxic M1 phenotype has been 
shown to persist longer than the M2 phenotype following TBI (Collins-Praino and Corrigan, 
2016; Kumar et al., 2016; Wang et al., 2013a) Furthermore, some studies have demonstrated 
that persistent neuroinflammation can occur decades following severe TBI or repetitive 
concussion (Collins-Praino and Corrigan, 2016; Coughlin et al., 2015; Ramlackhansingh et 
al., 2011). Physiologically, one explanation for the persistence of neuroinflammation 
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following repetitive TBI focuses on microglial priming. Microglial priming is a process in 
which microglia develop exaggerated immune responses and decreased activation thresholds 
following an insult such as TBI; therefore, neuroinflammation can be chronically 
exacerbated upon additional TBIs or systemic inflammation (Collins-Praino and Corrigan, 
2016).
3.2.4 Tau Phosphorylation—In direct relation to CTE, TBI also results in increased 
levels of total and phosphorylated tau. In human TBI, injury severity is correlated with 
increased tau phosphorylation, increased activity of the tau kinase GSK-3β, and decreased 
activity of the tau phosphatase, PP2A, (Yang et al., 2016). Tau pathology has been reported 
following cases of single severe TBI (Ikonomovic et al., 2004; Johnson et al., 2012; Uryu et 
al., 2007), in patients whom have died within six months of sustaining a concussion (McKee 
et al., 2014), and in young military veterans with a history of blast exposure (McKee and 
Robinson, 2014). Therefore, there is not only increasing interest in investigating the 
development of CTE-like tau pathology in animal models of single and repetitive TBI, but 
also in the development of tau as a biomarker for TBI (Section 5. Tau – A Biomarker for 
TBI). Figure 1 hypothesizes the possible contribution of single, or perhaps multiple, 
pathophysiological mechanisms to the development of CTE.
4. The Role of Tau in Cellular Dysfunction
The process in which acute TBI pathology develops into the chronic tau pathology seen in 
the tauopathies CTE and AD remains to be established, however, the mechanisms that can 
initiate formation of pathologic tau as well as the mechanisms by which tau can induce 
cellular dysfunction parallel many of the secondary injury mechanisms of TBI, including 
damage by ROS/RNS and LP-derived neurotoxic aldehydes, mitochondrial dysfunction, ER 
stress, calpain and caspase activation, and inflammation.
4.1 Oxidative Stress
Oxidative stress is elevated in several tauopathies (Alavi Naini and Soussi-Yanicostas, 2015; 
Castellani et al., 1995; Litvan, 2004; Martinez et al., 2008a). It is well known that in the 
tauopathy AD, Aβ is capable of inducing oxidative stress, a process which is hypothesized 
to be upstream of the formation of pathologic tau (Giraldo et al., 2014). Several studies 
confirm both the ability of oxidative stress to induce tau pathology and the ability of 
pathologic tau to induce oxidative stress, suggesting the possibility that in tauopathies such 
as CTE a self-propagating cycle of pathologic tau formation and oxidative stress occurs and 
leads to cellular dysfunction and neurodegeneration.
In-vitro, oxidative stress can induce both increases in tau aggregation and phosphorylation. 
Exposing tau isolated from bovine brain to iron-catalyzed oxidation results in dimerization, 
polymerization and formation of tau filaments (Troncoso et al., 1993), and in primary rat 
cortical neurons, oxidative stress (Fe2+/H2O2) increases tau phosphorylation by increasing 
activity of the tau kinase, GSK-3β, an effect which is attenuated by the GSK-3β inhibitor, 
lithium (Lovell et al., 2004). Interestingly, lithium also has the ability to attenuate tau 
pathology in-vivo by decreasing GSK-3β dependent tau phosphorylation and aggregation in 
transgenic tau mice (Perez et al., 2003). Additional in-vitro studies indicate that tau 
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phosphorylation is also induced by chronic oxidative stress. Inhibiting glutathione synthase 
in neuroblastoma cells induces a mild, chronic oxidative stress, which increases the activity 
of the tau kinase, JNK, decreases the activity of the tau phosphatase, PP2A, and results in 
increases in tau phosphorylation and tau aggregation (Su et al., 2010). Although these 
studies indicate oxidative stress has the ability to induce tau phosphorylation in-vitro, 
oxidative stress induced tau dephosphorylation has also been reported (Davis et al., 1997; 
Galas et al., 2006; Olivieri et al., 2001; Zambrano et al., 2004). However, dephosphorylation 
of tau following oxidative stress exposure seems to be limited to acute administration of 
H2O2.
In-vivo experiments also link tau phosphorylation to oxidative stress exposure. Transgenic 
mice deficient for the mitochondrial antioxidant enzyme, SOD2, have increases in 
mitochondrial-induced oxidative stress, which result in increased tau phosphorylation, an 
effect which is attenuated by antioxidant administration (Melov et al., 2007). Additionally, 
transgenic mice overexpressing the mutated form of human tau, P301S, show markers of 
oxidative stress such as, increased mitochondrial protein carbonyls and decreased SOD2, 
months prior to the appearance of tau hyperphosphorylation and tangle formation (Dumont 
et al., 2011).
While oxidative stress has a demonstrated ability to induce tau pathology, several studies 
show that tau itself has the ability to induce oxidative stress. In-vitro, overexpressing tau 
impairs trafficking of peroxisomes, organelles responsible for H2O2 detoxification and 
results in increased susceptibility to H2O2-induced oxidative stress (Alavi Naini and Soussi-
Yanicostas, 2015; Stamer et al., 2002). Tauopathy animal models also suggest the ability of 
tau to induce oxidative stress. Cultured neurons obtained from transgenic rats expressing a 
truncated form of human tau analogous to that found in AD have increased levels of ROS 
and are more susceptible to oxidative stress, effects which are likely the result of decreased 
numbers of mitochondria and abnormal mitochondrial distribution (Alavi Naini and Soussi-
Yanicostas, 2015; Cente et al., 2006). Furthermore, transgenic mice overexpressing mutant 
human tau, P301L, also show increased generation of ROS, another consequence of 
mitochondrial dysfunction (Alavi Naini and Soussi-Yanicostas, 2015; David et al., 2005).
In summary, oxidative stress is well-established to occur in neurodegenerative tauopathies, 
and there are several mechanisms by which oxidative stress can induce tau phosphorylation 
and aggregation and by which pathologic tau can induce oxidative stress (Figure 2). 
Therefore, a primary event capable of inducing either oxidative stress or tau dysfunction, 
such as TBI, could set off a chronic and self-propagating cyclical cascade of oxidative stress 
and pathologic tau formation.
4.2 Peroxynitrite
Oxidative stress is often used as a broad term which encompasses a multitude of reactive 
species, one specific reactive species being PN. The PN derived radical, NO•2, is capable of 
nitrating tyrosine at the 3 position, thus forming 3-NT, a specific marker of PN-induced 
cellular damage (Hall et al., 2010). 3-NT modified tau has been identified in a variety of 
tauopathies, including AD, frontotemporal dementia, and Pick's disease (Horiguchi et al., 
2003; Smith et al., 1997).
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Peroxynitrite is capable of inducing tau dysfunction through both oxidation and nitration 
mechanisms (Reynolds et al., 2005; Reynolds et al., 2006). In-vitro, cysteine oxidation of 
tau by PN results in formation of disulfide crosslinks, tau oligomerization, and decreased 
microtubule assembly (Landino et al., 2004). PN can also promote tau oligomerization 
through addition of tyrosyl radicals which results in formation of 3,3′-dityrosine irreversible 
crosslinks and stabilization of insoluble tau filament aggregates characteristic of late stage 
paired helical filaments (PHF) (Reynolds et al., 2005; Reynolds et al., 2006). Furthermore, 
although PN-derived NO•2 nitration of tau has been shown to inhibit tau polymerization 
(Reynolds et al., 2005), 3-NT modification of tau does result in disrupted binding of tau to 
microtubules and inhibition of tubulin assembly (Reynolds et al., 2006; Zhang et al., 2005).
Peroxynitrite has also been shown to modify tau in-vivo. Injection of the PN donor, SIN-1, 
into rat hippocampus results in both nitration and hyperphosphorylation of tau, and 
increased activation of the tau kinases, GSK-3β and p38 MAPK, processes are attenuated by 
pre-administration of the PN scavenger, uric acid (Zhang et al., 2006). SIN-1 administration 
increased levels of nitrated p85, a regulator of GSK-3β, suggesting that PN is capable of 
inducing tau hyperphosphorylation by nitration of upstream proteins in tau phosphorylation 
cascade (Zhang et al., 2006). Furthermore, SIN-1 also led to a decrease in proteasome 
activity, which combined with the fact that the nitrated form of tau is less susceptible to 
proteasomal degradation, resulted in an increase in tau aggregation (Zhang et al., 2006).
In summary, there are several mechanisms by which the reactive species, PN, can induce tau 
pathology, including oxidation, nitration, and induction of tau hyperphosphorylation, 
processes which lead to accumulation of toxic tau aggregates and/or destabilization of 
microtubules. PN is generated following TBI; therefore it is possible that the PN formed 
acutely following TBI initiates tau dysfunction, while other mechanisms of PN generation, 
such as continued mitochondrial dysfunction, contribute to chronic PN-induced tau 
dysfunction as suggested in Figure 3.
4.3 Lipid Peroxidation-Derived Neurotoxic Aldehydes
Lipid peroxidation-derived aldehydes have been found to be elevated in the brains of several 
tauopathies (Butterfield et al., 2010; Lovell et al., 2001; Markesbery and Lovell, 1998; 
Martinez et al., 2008a; Martinez et al., 2008b; Montine et al., 1997; Muntane et al., 2006; 
Odetti et al., 2000; Sayre et al., 1997). In fact, in PSP, a tauopathy with paired helical 
filament morphology distinct from AD, significant increases in 4-HNE are correlated with 
tau aggregation, suggesting that accumulation of 4-HNE may contribute to impairment of 
tau degradation (Odetti et al., 2000).
The LP-derived aldehydes 4-HNE and acrolein are both capable of inducing tau pathology. 
In-vitro, administration of 4-HNE to cultured rat hippocampal neurons results in direct 
binding of 4-HNE to tau, preventing dephosphorylation of tau by alkaline phosphatases 
(Mattson et al., 1997). Acrolein, a more potent neurotoxic aldehyde than HNE (Vaishnav et 
al., 2010), also induces hyperphosphorylation of tau, both in neuroblastoma cells and in 
cultured cortical mouse neurons, an effect which can be attenuated by inhibiting the tau 
kinases, GSK-3β and p38 MAPK (Gomez-Ramos et al., 2003).
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In addition to inducing tau hyperphosphorylation, 4-HNE and acrolein are also capable of 
promoting tau aggregation. In P19 neuroglial cultures, 4-HNE addition results in 
cytotoxicity and formation of high molecular weight tau species characteristic of 
neurofibrillary tangles (Montine et al., 1996). However, the effect of 4-HNE on tau 
aggregation is greatest for tau which has already been hyperphosphorylated. In-vitro, 
administration of 4-HNE promotes assembly of phosphorylated tau, but not native tau, into 
neurofibrillary tangle-like fibrillary polymers (Perez et al., 2000). Phosphorylation of tau is 
also required in order for 4-HNE to induce conformational changes to tau, such as the Alz50 
epitope conformational change characteristic of early AD (Liu et al., 2005; Takeda et al., 
2000). Therefore, 4-HNE may play a role in NFT formation by stabilizing pathologic tau 
confirmations (Liu et al., 2005). However, 4-HNE does not further enhance aldehydic 
modification of paired helical filaments, suggesting that paired helical filaments are either 
already extensively modified by aldehydes or that they are in a confirmation which prevents 
further aldehyde modifications (Liu et al., 2005). Acrolein also promotes tau aggregation in 
a concentration-dependent manner, with the fastest aggregation rates occurring in 
pseudophosphorylated tau, further suggesting that hyperphosphorylation of tau increases its 
susceptibility to aldehyde-induced aggregation (Kuhla et al., 2007).
While LP-derived aldehydes have a demonstrated ability to induce tau pathology, tau itself 
can enhance formation of LP-derived aldehydes. For example, in brain homogenates derived 
from transgenic mice overexpressing mutant human tau, P301L, ferric iron-induced LP 
results in increased formation of the LP-derived aldehyde, malondialdehyde, compared to 
wild-type mice (David et al., 2005).
In summary, LP-derived aldehydes are known to be present in human tauopathies, and LP-
derived aldehydes, such as 4-HNE and acrolein, are capable of inducing tau phosphorylation 
and promoting and stabilizing tau aggregation, in particular the aggregation of 
hyperphosphorylated tau. Therefore, it is possible that following TBI, increases in 4-HNE 
and acrolein and increases in hyperphosphorylated tau work synergistically to promote tau 
aggregation, while other mechanisms of 4-HNE and acrolein generation, such as continued 
mitochondrial dysfunction and tau-induced LP, contribute to a chronic, self-promoting and 
cyclic cascade of LP and pathologic tau formation (Figure 4).
4.4 Mitochondrial Dysfunction
Alterations in mitochondrial function are known to occur in the tauopathies, AD and FTD 
(Baloyannis, 2006; David et al., 2005), and in normal aging (Swerdlow, 2011). Several 
studies indicate that mitochondrial dysfunction is capable of inducing tau dysfunction, and 
that tau itself is capable of inducing mitochondrial dysfunction.
Impairment of oxidative phosphorylation can lead to tau dysfunction and pathologic tau 
formation both in-vitro and in-vivo. For example, in primary rat striatal rat neurons, 
inhibition of complex-I, inhibition of complex-II, or uncoupling of oxidative 
phosphorylation leads to decreased ATP production, cellular death and retrograde transport 
of tau and mitochondria from the axons to the soma (Escobar-Khondiker et al., 2007). In 
fact, complex-I inhibited neurons contain somal mitochondria which associate with tau at 
the outer mitochondrial membrane (Escobar-Khondiker et al., 2007). In-vivo, inhibition of 
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complex-I can also induce tau pathology. Chronically infusing the complex-I inhibitor, 
rotenone, into rats results in cell death, motor dysfunction, and increases in cytosolic tau, 
phosphorylated tau, and neuronal, glial, and oligodendrocytic tau fibrils (Hoglinger et al., 
2005). Furthermore, increased levels of the PN marker, 3-NT, and ubiquitin, a marker for 
defective protein degradation, are found within cells containing pathologic tau (Hoglinger et 
al., 2005). Mitochondrial dysfunction is known to lead to PN formation (Bringold et al., 
2000; Radi et al., 2002) and can indirectly reduce proteosomal activity (Hoglinger et al., 
2005). Therefore, it is possible that complex-I induced mitochondrial dysfunction can lead 
to formation of pathologic tau through a combination of mechanisms including 
mitochondrial and tau redistribution, generation of reactive nitrogen species, and impairment 
of proteosomal degradation pathways.
Pathologic tau has also been observed in transgenic mice lacking the mitochondrial 
antioxidant enzyme SOD2. Mitochondrial SOD2 catalyzes the dismutation of superoxide 
(O2•-), formed when single electrons leak from complex I of the electron transport chain 
(Brand et al., 2004), to the less reactive oxygen species, H2O2 (Flynn and Melov, 2013). 
Thus, SOD2 is an essential enzyme without which the undismutated O2•- wil react with 
mitochondrial NO• to form the reactive nitrogen species PN. . However, pharmacological 
administration of the catalytic antioxidant EUK-189 is able to attenuate tau phosphorylation 
in SOD2 deficient mice (Melov et al., 2007), confirming that mitochondrial generated O2•- 
or downstream PN (formed upon reaction of mitochondrial O2•- and NO•) is capable of 
driving tau phosphorylation (Melov et al., 2007). Additional evidence supports the theory 
that mitochondrial dysfunction can induce tau phosphorylation. In transgenic mice 
overexpressing the human tau mutation, P301S, mitochondrial abnormalities, including 
carbonyl modification of mitochondrial proteins and decreases in mitochondrial enzyme 
activities, precede tau hyperphosphorylation and tangle formation by at least three months 
(Dumont et al., 2011). However, while it is likely that the mitochondrial abnormalities 
contributed to pathologic tau development, it is also likely that the overexpression of 
mutated human tau itself induces mitochondrial abnormalities.
Multiple studies provide evidence that tau can induce mitochondrial dysfunction. 
Mitochondria are synthesized in neuronal cell bodies and then transported throughout the 
neuron along microtubules by the anterograde motor protein, kinesin (Chang et al., 2006; 
Morris and Hollenbeck, 1995), while damaged mitochondria are transported toward the 
soma by the retrograde motor protein, dynein (Miller and Sheetz, 2004). Therefore, neuronal 
health relies extensively on proper axonal transport of mitochondria. In CTE, fast axonal 
transport along microtubules is impaired, with decreases being seen both in kinesin and 
dynein (Kokjohn et al., 2013). Tau is primarily found in axons, functioning to stabilize 
microtubules (Maccioni and Cambiazo, 1995); however, tau also serves to regulate the 
attachment and detachment of motor proteins (Trinczek et al., 1999). Therefore, it has been 
hypothesized that overexpression of tau or accumulation of pathologic tau can impair axonal 
transport of mitochondria to the synapse, resulting in decreased synaptic ATP, calcium 
dysregulation and neurodegeneration (Sheng and Cai, 2012). However, it should be noted 
that in addition to mitochondria, tau-induced impairment of axonal transport affects 
additional organelles, vesicles, and proteins, and that each likely contributes to their own 
downstream pathologies. For example, tau overexpression can inhibit trafficking of 
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peroxisomes, neurofilaments, Golgi-derived vesicles, the ER, and amyloid precursor protein 
(APP) (Darios et al., 2005; Ebneth et al., 1998; Stamer et al., 2002), the precursor to Aβ, a 
pathologic species found in the tauopathy AD and in a subset CTE cases.
In regard specifically to axonal transport of mitochondria, several mechanisms by which tau-
induced impairment of axonal transport have been reported. In-vitro, overexpression of tau 
in neuroblastoma cells leads to preferential impairment of anterograde mitochondrial 
transport, resulting in mitochondria that are clustered near nuclei but absent in neurites 
(Ebneth et al., 1998). The degree to which tau overexpression interferes with mitochondrial 
transport is influenced by the number of microtubule binding domain repeats. For instance, 
overexpression of either 3R or 4R tau leads to redistribution of mitochondria from axons to 
the soma (Stoothoff et al., 2009); however, 4R tau, the isoform expressed to a greater degree 
in AD and CTE (McKee et al., 2014; Schmidt et al., 2001) has the greatest effect on 
redistribution (Stoothoff et al., 2009). The N-terminus of tau has also been shown to be 
sufficient for inhibiting anterograde transport (LaPointe et al., 2009). In fact, filamentous 
tau, which contains an exposed N-terminus, inhibits kinesin-dependent fast axonal transport, 
whereas monomeric tau confirmations with unexposed N-terminal regions do not (LaPointe 
et al., 2009). Hyperphosphorylation of tau at AD-specific sites also results in decreased 
mitochondrial transport due to extension of the N-terminal projection domain and expansion 
of inter-microtubule distances (Shahpasand et al., 2012). Additional studies confirm the 
ability of phosphorylated tau impair anterograde transport. Inhibition of anterograde 
transport by filamentous tau is dependent upon on activation of the tau kinase, GSK-3β 
(LaPointe et al., 2009). In PC12 cells, ceramide-induced CDK5-dependent tau 
phosphorylation results in dissociation of phosphorylated tau from the microtubules, 
clustering of mitochondria and ER near the centrosome, and cell death, effects which are 
attenuated by preventing tau phosphorylation (Darios et al., 2005).
Tau-induced impairment of mitochondrial transport likely has pathologic implications 
beyond decreased delivery of mitochondria to the synapse. For example, the clustering of 
mitochondria and ER near the centrosome in PC12 cells results in an increase in 
mitochondria-ER associations, neurotoxic transfer of Ca2+ from the ER to the mitochondria, 
and induction of apoptosis (Darios et al., 2005). Pathologic mitochondria-ER associations 
have also been observed in the soma of spinal motor neurons in transgenic mice 
overexpressing the human tau mutation, P301L (Perreault et al., 2009), and correlate with 
accumulation of hyperphosphorylated tau at the surface of the rough ER (rER) (Perreault et 
al., 2009). In fact, hyperphosphorylated tau is found on the surface of rER in the tauopathy, 
AD (Perreault et al., 2009). Because mitochondria-ER associations require the ER to be 
absent ribosomes, it is possible that tau is capable of inducing mitochondria-ER associations 
by displacing ribosomes from the ER surface (Perreault et al., 2009).
In addition to impairment of mitochondrial transport and alterations in mitochondrial-ER 
dynamics, other tau-induced mitochondrial impairments have been reported such as 
abnormal morphology. For example, neurons from transgenic mice overexpressing the 
human tau mutation, P301L, have decreased numbers of mitochondria and mitochondria 
which have abnormally swollen morphology (Yoshiyama et al., 2007).
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Tau-induced decreases in oxidative phosphorylation capacity have also been reported. The 
mitochondria from P301L mice have reductions in complex I (David et al., 2005; Rhein et 
al., 2009) and complex V (ATP synthase) protein and activity levels (David et al., 2005). 
Additionally, aged P301L mice have decreases in ATP production and increases in ROS due 
to decreases in complex-I driven respiration (David et al., 2005). Importantly, reductions in 
complex V (ATP synthase) have also been seen in the human tauopathy, FTD (David et al., 
2005).
Although many studies that investigate the effect of tau on mitochondrial function rely on 
mutated forms of human tau, the mutant tau constructs, such as P301, do induce tau 
hyperphosphorylation. Therefore, the mutant tau constructs are representative of non-
genetic, hyperphosphorylated tau disease states. However, the possibility exists that mutated 
tau isoforms cause greater mitochondrial dysfunction than wild type tau. For example, stable 
overexpression of human mutant tau, P301L, into SY5Y cells results in complex I 
impairment, decreased ATP production, increased susceptibility to oxidative stress, 
abnormal morphology, and fission-fusion dysfunction (Schulz et al., 2012); however, 
overexpression of wild-type 4R human tau results in increases in complex I activity, normal 
morphology and normal fission-fusion dynamics (Schulz et al., 2012).
Tau oligomers, which have been implicated as the species responsible for tau-induced 
neurotoxicity (Spires-Jones et al., 2011), are also capable of inducing mitochondrial 
dysfunction. Injections of full-length human tau oligomers, but not tau fibrils or monomers, 
into mouse hippocampi induce memory impairment, neurodegeneration, loss of synaptic 
proteins, and mitochondrial dysfunction (Lasagna-Reeves et al., 2011). Specifically, the tau 
oligomers co-localized with mitochondria, decreasing complex I protein levels, and 
activating the intrinsic apoptotic protease, caspase-9 (Lasagna-Reeves et al., 2011). 
However, complex V protein levels were not altered, suggesting that complex I dysfunction 
occurs prior to tau-induced complex V dysfunction and ATP depletion (Lasagna-Reeves et 
al., 2011).
Truncated tau fragments are also capable of inducing mitochondrial dysfunction. In 
immortalized cortical neurons, Asp421 tau, a mutant mimicking C-terminus caspase-3 
cleavage of tau at Asp421, induces mitochondrial fragmentation, decreases mitochondrial 
calcium buffering capacity, and increases production of mitochondrial ROS (Quintanilla et 
al., 2009), effects which are attenuated by administration of the calcineurin inhibitors 
cyclosporine A (CsA) or FK506, suggesting that the calcium-dependent phosphatase, 
calcineurin, plays a role in caspase-cleaved tau induction of mitochondrial dysfunction 
(Quintanilla et al., 2009). Tau is a known calcineurin substrate; therefore, it is possible that 
caspase-cleaved tau interacts differentially with calcineurin, increasing its activity level 
toward substrates which effect mitochondrial fragmentation (Quintanilla et al., 2009). 
Interestingly, both CsA and FK506 are neuroprotective in experimental TBI (Kilbaugh et al., 
2011; Kulbe et al., 2016; Marmarou and Povlishock, 2006; Mbye et al., 2009; Mbye et al., 
2008; Reeves et al., 2007; Sullivan et al., 2011), and CsA has been shown to attenuate levels 
of cleaved tau in the hippocampus of rats following severe controlled cortical impact injury 
(CCI) (Gabbita et al., 2005).
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In addition to C-terminal cleavage, truncated tau fragments can also be generated by N-
terminal processing. Although this process is not well understood, caspases, such as 
caspase-6 have the ability to cleave tau at the N-terminus (Horowitz et al., 2004), and N-
terminal tau fragments have been reported to induce mitochondrial dysfunction. For 
example, addition of the NH2-26-44 tau fragment to cerebellar granule neuron homogenates 
results in decreases in cytochrome oxidase (COX) activity, adenine nucleotide translocator 
(ANT) activity, and ANT-dependent impairment of oxidative phosphorylation (Atlante et al., 
2008). Importantly, N-terminal tau fragments have been identified in AD and other 
tauopathies (Amadoro et al., 2010). In fact, in AD, a 20-22kD NH2-tau fragment is highly 
enriched in synaptosomes, localizing with synaptic mitochondria, and correlating with 
synaptic and mitochondrial dysfunction (Amadoro et al., 2010). Synapses have high 
metabolic demands, met by enrichment of synaptic mitochondria (Khatri and Man, 2013; 
MacAskill et al., 2010). Not only are synaptic mitochondria essential for proper 
neurotransmission (Sheng and Cai, 2012) and synaptic plasticity (Cheng et al., 2010; 
MacAskill et al., 2010; Sheng and Cai, 2012), but their dysfunction is implicated in 
neurodegeneration (Cheng et al., 2010; Sheng and Cai, 2012). Therefore, localization of the 
20-22kD NH2-tau with synaptic mitochondria has important implications for synaptic 
health, especially considering the fact that 20-22kD NH2-tau is capable of inducing 
mitochondrial dysfunction. In vitro, the 20-22kD NH2-tau fragment induces abnormal 
mitochondrial morphology, increases mitochondrial fragmentation, decreases mitochondrial 
fusion, enhances redistribution of mitochondria to the soma, decreases mitochondrial protein 
and mtDNA copy number, and enhances mitophagy, effects which correlate with in-vitro 
synaptic pathology and oxidative stress (Amadoro et al., 2014).
In addition to truncated tau species, phosphorylated tau has also been implicated in 
alteration of mitochondrial fission-fusion dynamics. Specifically, in the tauopathy AD, 
phosphorylated tau interacts with Drp1, a mitochondrial fission GTPase, and is associated 
with increases in GTPase activity indicative of mitochondrial fission, suggesting that 
phosphorylated tau may enhance mitochondrial fragmentation through interaction with Drp1 
(Manczak and Reddy, 2012).
In summary, mitochondrial dysfunction is known to occur in human tauopathies, and there 
are several mechanisms by which mitochondrial dysfunction can induce tau pathology and 
by which pathologic tau species can induce mitochondrial dysfunction. Therefore, a primary 
event capable of inducing mitochondrial dysfunction or formation of pathologic tau species, 
such as TBI, could set off a self-propagating, cyclical cascade of mitochondrial dysfunction 
and pathologic tau formation, which work synergistically to induce cellular damage. In fact, 
in transgenic mice expressing mutations which induce both mitochondrial dysfunction and 
tau pathology, neurodegeneration and oxidative stress are increased over either mutation 
alone (Kulic et al., 2011). Furthermore, in addition to a self-propagating, cyclical cascade of 
mitochondrial-tau dysfunction, because mitochondrial impairment results in production of 
species capable of inducing damage to mitochondrial DNA (mtDNA), which encodes for 
electron transport chain proteins (Dalleau et al., 2013; Hall et al., 2010), mitochondrial 
dysfunction is capable of enhancing and perpetuating its own chronic damage. In fact, 
accumulations in mtDNA damage have been hypothesized to contribute to both aging and 
neurodegenerative disease (Keogh and Chinnery, 2015).
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4.5 Endoplasmic Reticulum Stress
ER stress has been documented in several tauopathies, including AD, FTD, and CTE, and 
correlates with tau hyperphosphorylation (Hoozemans and Scheper, 2012; Hoozemans et al., 
2009; Lucke-Wold et al., 2016; Nijholt et al., 2012). ER dysfunction has been reported to 
occur both upstream and downstream of pathologic tau formation (Ho et al., 2012). 
Upstream of tau, pharmacological induction of ER stress increases tau phosphorylation both 
in-vitro and in-vivo (Fu et al., 2010; Ho et al., 2012; Lin et al., 2014). One mechanism by 
which ER stress can increase tau phosphorylation is through activation of the tau kinase, 
GSK-3β (Fu et al., 2010; Lin et al., 2014). However, pathologic tau species can also induce 
ER dysfunction. The ER is responsible for protein folding and degradation; therefore, ER 
stress results in the build-up of misfolded and unfolded proteins, inhibition of ER-associated 
degradation (ERAD), initiation of the Unfolded Protein Response (UPR), and decreased 
protein synthesis (Abisambra et al., 2013; Radford et al., 2015).
Tau is capable of activating the UPR in-vitro. Pharmacologic induction of tau 
phosphorylation in primary rat cortical neurons results in UPR activation (Ho et al., 2012). 
Similarly, stable expression of tau in HEK cells activates the UPR and is accompanied by 
increased ubiquitin levels suggestive of ERAD impairment (Abisambra et al., 2013). In-vivo, 
the UPR is known to be increased in both transgenic tau animal models and human 
tauopathies (Abisambra et al., 2013; Hoozemans and Scheper, 2012; Hoozemans et al., 
2009; Nijholt et al., 2012; Radford et al., 2015). It has been hypothesized that the increased 
UPR seen in tauopathies is the result of tau-induced ERAD impairment (Abisambra et al., 
2013). For example, transgenic mice overexpressing human mutant tau, P301L, show ERAD 
impairment concomitant with associations between tau and the ERAD hetereocomplex 
(Abisambra et al., 2013). However, activation of UPR in tauopathies may also be due to the 
buildup of misfolded tau proteins (Radford et al., 2015). UPR activation has also been 
suggested to play a direct role in neurotoxicity. In fact, pharmacologic inhibition of the UPR 
in P301L mice decreases tau phosphorylation, neurodegeneration, and behavioral 
impairment (Radford et al., 2015).
An additional mechanism by which tau induced ER dysfunction can contribute to cellular 
dysfunction is inhibition of protein synthesis. Microsomes are vesicle-like fragments which 
contain ER and ribsosomes. In brain microsomes isolated from the tauopathy, AD, 
oligomeric tau associates more strongly with ribosomes than in control brains, suggesting 
that pathologic tau may have an effect on RNA translation (Meier et al., 2016). In fact, in-
vitro, wild type, mutant, and oligomeric tau are all able to reduce RNA translation (Meier et 
al., 2016), and in primary neurons cultured from transgenic mice overexpressing human 
mutant tau, P301L, there are both decreases in RNA translation and protein levels (Meier et 
al., 2016). Specifically, there are marked decreases in the protein PSD-95, a post-synaptic 
protein important in learning and memory (Meier et al., 2016).
Soluble tau oligomers and truncated tau forms have been specifically implicated in tau 
induced ER dysfunction. Depleting soluble tau both in cell culture and in P301L mice 
reduces UPR activation and inhibition of ERAD, suggesting soluble tau oligomers rather 
than insoluble tau aggregates are responsible for tau-induced ER dysfunction (Abisambra et 
al., 2013). In regards to truncated tau isoforms, inducing ER stress in immortalized cortical 
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neurons expressing Asp-421 truncated tau, which mimics caspase-3 cleavage, results in 
increased cellular toxicity and caspase-3 activation compared to cells expressing full length 
tau (Matthews-Roberson et al., 2008). In fact, ER stress itself has the capability of inducing 
the caspase-3 activation (Morishima et al., 2002; Song et al., 2002) which leads to tau 
truncation.
In summary, ER stress is known to occur in several tauopathies, including CTE, and there 
are several mechanisms by which ER stress can induce tau pathology and by which 
pathologic tau species can induce ER dysfunction. Therefore, as summarized in Figure 5, a 
primary event capable inducing ER stress or tau pathology, such as TBI, could set off a 
chronic and self-propagating cascade of ER dysfunction and pathologic tau formation, 
which results in protein accumulation, decreased protein synthesis, and cellular dysfunction.
4.6 Calpain Activated Proteolysis
Tau is a known substrate of the calcium-dependent cysteine protease, calpain (Johnson et al., 
1989; Litersky et al., 1993; Yang and Ksiezak-Reding, 1995). Calpain cleavage of tau results 
in the formation of a 35kD tau fragment (Liu et al., 2011) and a 17kD tau fragment, 
purported to be between 10-17kD (Garg et al., 2011; Park and Ferreira, 2005). Increased 
calpain activity and depletion of the endogenous calpain inhibitor, calpastatin, have been 
found in the tauopathy, AD, (Grynspan et al., 1997; Rao et al., 2008; Saito et al., 1993; Tsuji 
et al., 1998) and the presence of the 17kD tau fragment correlates with increases in calpain 
activity in a variety of tauophathies, including AD, FTD and dementia pugilistic (i.e. CTE) 
(Ferreira and Bigio, 2011).
The 17kD tau fragment has a decreased association with the microtubules and accumulates 
in the perikarya (Canu et al., 1998). In-vitro, glutamate and thapsigargin induced increases 
in calcium have been shown to induce formation of calpain-cleaved 17kD tau (Garg et al., 
2011). The 17kD tau fragment has been reported for form prior to increases in tau 
phosphorylation (Park and Ferreira, 2005), and is suspected of being neurotoxic (Park and 
Ferreira, 2005; Park et al., 2007; Sinjoanu et al., 2008). For example, in-vitro, Aβ induces 
calpain activation in cultured hippocampal neurons, leading to formation of 17kD tau and 
neurodegeneration, affects which are attenuated by inhibiting calpain activation (Park and 
Ferreira, 2005; Park et al., 2007; Sinjoanu et al., 2008). However, other studies have shown 
that 17kD tau does not induce toxicity in-vitro and is equally expressed in the brains of AD 
and healthy controls, suggesting that 17kD tau is a marker for calpain activation but does not 
have a direct role in neurotoxicity (Garg et al., 2011).
In addition to cleaving tau, calpain has also been identified as an upstream activator of 
extracellular-regulated kinase (ERK) (Veeranna et al., 2004), which is capable of 
phosphorylating tau (Fang et al., 2010; Qi et al., 2016), In fact, increases in active ERK 
expression are associated with early tau deposition in neurons and glia in several tauopathies 
(Ferrer et al., 2001).
Despite controversy surrounding the role of the calpain generated 17kD tau fragment in 
neurotoxicity, both increases in calpain and 17kD tau have been identified in human 
tauopathies. Due to increases in intracellular calcium levels, calpain is highly activated 
Kulbe and Hall Page 19
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
following TBI (Deng et al., 2007; Thompson et al., 2006); therefore it is possible that TBI 
initiates formation of calpain-cleaved 17kD tau, whereas chronic generation of 17kD tau 
could be the result of calpain activation by calcium derived from chronically dysfunctional 
calcium buffering organelles suspected of having self-propagating, cyclic interactions with 
pathologic tau, such as the mitochondria and ER (Figure 6).
4.7 Caspase Activated Proteolysis
Tau is a known substrate of the caspase proteases (Fasulo et al., 2000; Park et al., 2007), 
which are well known for their role in apoptosis. The most well characterized caspase 
cleavage site on tau is Asp421, located on the c-terminus end. Multiple caspases, including 
caspase 3, can cleave tau at Asp421 (Gamblin et al., 2003), which results in a tau fragment 
of 50kD (Chung et al., 2001; Park et al., 2007). However, tau can also undergo n-terminal 
processing by caspases, such as caspase-6 (Horowitz et al., 2004). Caspase cleaved tau is 
found in several tauopathies (Guillozet-Bongaarts et al., 2007; Newman et al., 2005), and is 
inversely correlated with cognitive function in the tauopathy, AD (Rissman et al., 2004), 
with formation of Asp421 truncated tau considered to occur relatively early in the disease 
process (Guillozet-Bongaarts et al., 2005; Rissman et al., 2004). It is hypothesized that 
accumulation of Asp421 truncated is the result of dysregulation of autophagy, a process 
known to occur in the tauopathy, AD (Nixon, 2006). In fact, in immortalized cortical 
neurons, stably expressed Asp421 truncated tau is preferentially degraded by autophagy, 
while full length tau is dependent on proteasomal degradation (Dolan and Johnson, 2010).
Several lines of evidence suggest that Asp421 truncated tau is pathologic. In-vitro, the c-
terminus of tau is responsible for inhibiting polymerization of tau, suggesting that Asp421 
truncated tau has enhanced polymerization properties (Berry et al., 2003). In fact, Asp421 
truncated tau assembles into filaments at a faster rate and to a higher degree than full length 
tau (Gamblin et al., 2003; Rissman et al., 2004). Furthermore, full length tau undergoes 
enhanced filament formation in the presence of Asp421 truncated tau, suggesting that 
Asp421 truncated tau may be able to seed filament formation of other tau species (Rissman 
et al., 2004). In-vitro, overexpression of Asp421 truncated tau, representative of caspase-3 
cleaved tau, results in increased apoptosis (Chung et al., 2001; Fasulo et al., 2000). 
Caspase-3 is an executioner caspase in the apoptotic cascade; therefore, the fact that 
caspase-3 cleaved tau is capable of enhancing apoptosis suggests that caspase-3 and Asp421 
truncated tau may be involved in a chronic, self-propagating apoptotic cascade (Fasulo et al., 
2000). Additionally, as previously discussed, caspase cleaved tau fragments are also capable 
of inducing mitochondrial dysfunction (Quintanilla et al., 2009) and ER stress (Matthews-
Roberson et al., 2008).
Evidence suggests that non-truncated tau forms can also initiate caspase activation and tau 
truncation. For example, overexpressing human mutant tau P301L in mice results in 
apoptosis, caspase-3 activation, and appearance of caspase truncated tau (de Calignon et al., 
2010; Ramalho et al., 2008). Similarly, overexpression of human 4R tau results in caspase 
activation, although total numbers of caspase bearing neurons are low (de Calignon et al., 
2010). Therefore, it is possible that, in-vivo, full-length pathologic tau, particularly soluble 
pre-tangle tau species, are capable of activating caspase-3, which results in formation of 
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distinct truncated tau species. In fact, suppression of tau in P301L mice decreases caspase 
activation despite the continued presence of neurofibrillary tangles (de Calignon et al., 
2010).
Although formation of caspase truncated tau is considered to occur early in the disease 
process (Guillozet-Bongaarts et al., 2005; Rissman et al., 2004), Asp421 truncated tau is still 
capable of inducing tau phosphorylation and conformational change (de Calignon et al., 
2010) and can be the subject of phosphorylation and conformation change itself (Rissman et 
al., 2004). However, similar to human studies, transgenic animal models of tauopathy 
suggest that formation of caspase truncated tau occurs prior to tau aggregation and correlates 
with cognitive decline. In fact, in P301L mice, caspase cleavage of tau proceeds 
neurofibrillary tangle formation (de Calignon et al., 2010; Ramalho et al., 2008), and is 
coincident with the beginnings of cognitive impairment (Ramalho et al., 2008). Furthermore, 
animal models confirm in-vitro findings that caspase truncated tau can seed filament 
formation of full length tau (Gamblin et al., 2003; Rissman et al., 2004). For example, 
virally overexpressing Asp421 tau in wild type mice results in formation of tau aggregates 
which contain both Asp421 truncated and full length tau (de Calignon et al., 2010).
As illustrated in Figure 7, tau is a substrate for the apoptotic caspase proteases and caspase 
truncated tau is present in human tauopathies. Additionally, caspase cleaved can induce 
cellular dysfunction. Apoptosis and caspase activation occurs following TBI; therefore, it is 
possible that TBI-induced caspase activation can initiate formation of caspase cleaved tau, 
whereas long-term generation of caspase truncated tau could be the result of chronic caspase 
activation due to chronic mitochondrial dysfunction or ER stress, organelles suspected of 
having self-propagating, cyclic interactions with pathologic tau. In fact, in P301L mice, 
activated executioner caspases can be found in neurons containing late stage neurofibrillary 
tangles, despite the absence of apoptosis (Spires-Jones et al., 2008). Furthermore, because 
caspase truncated tau is capable of activating caspase-3, impairing mitochondrial function, 
and enhancing ER stress, it is possible that caspase truncated tau itself can self-propagate its 
formation.
4.8 Neuroinflammation
Neuroinflammation occurs in multiple tauopathies including CTE, AD, PSP, Pick's disease, 
and corticobasal degeneration (Daneshvar et al., 2015; Ishizawa and Dickson, 2001; Sasaki 
et al., 2008; Zilka et al., 2009a). Astrocytes and microglia make up two of the most 
important cells of the CNS innate immune system. Astrocytes containing pathologic tau 
have been identified in several tauopathies, including CTE (Kahlson and Colodner, 2015; 
McKee et al., 2016). Similarly, microglia are activated in CTE and other tauopathies (Cherry 
et al., 2016; Faden and Loane, 2015; Ishizawa and Dickson, 2001; Saing et al., 2012; Sasaki 
et al., 2008; Zilka et al., 2009a). Evidence suggests that neuroinflammation can both induce 
tau pathology and be induced by pathologic tau species.
Under physiologic conditions astrocytes contain limited amounts of tau protein, and tau is 
not considered to be a major component of the astrocyte cytoskeleton (Kahlson and 
Colodner, 2015). However, in CTE and other tauopathies, hyperphosphorylated tau is 
present in astrocytes (Kahlson and Colodner, 2015; McKee et al., 2016). Although astrocytic 
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tau pathology is not well defined in CTE, supporting neuropathological criteria for the 
diagnosis of CTE includes p-tau positive thorned astrocytes located at the glial limitans in 
the subpial and periventricular regions (McKee et al., 2016). Additionally, the astrocytic tau 
of CTE is known to be composed mainly of the 4R subtype (McKee and Robinson, 2014).
Although the phenotypes of the astrocytes containing hyperphosphorylated tau vary between 
tauopathies, thorned astrocytes, such as those characteristic of CTE, morphologically 
resemble reactive astrocytes and therefore may be indicative of a neuroinflammatory 
response similar to gliosis (Kahlson and Colodner, 2015), a process known to occur 
following TBI (Burda et al., 2016). The presence of hyperphosphorylated tau within 
astrocytes is hypothesized to have several consequences for astrocytic function (Kahlson and 
Colodner, 2015). Astrocytes assist in maintenance of the blood-brain barrier; therefore, it is 
possible that astrocytic tau pathology can lead to blood-brain barrier dysfunction (Kahlson 
and Colodner, 2015). For example, overexpressing human tau in the astrocytes of mice 
results in mild blood-brain barrier disruption in areas of extensive astrocytic tau pathology 
(Forman et al., 2005). In addition to maintenance of the blood-brain barrier, astrocytes 
remove excessive extracellular glutamate; therefore, it is possible that astrocytic tau 
pathology can lead to impairment of extracellular glutamate removal, resulting in neuronal 
excitotoxicity and synaptic dysfunction (Kahlson and Colodner, 2015). In fact, 
overexpressing either human wild-type or mutant P301L tau in the astrocytes of mice results 
in a decrease in astrocyte glutamate transporter expression and activity which correlates with 
behavioral impairment (Dabir et al., 2006). Furthermore, overexpressing tau in astrocytes 
leads to astrocyte degeneration both in-vitro and in-vivo (Higuchi et al., 2002; Yoshiyama et 
al., 2003), and overexpressing human tau in the astrocytes of mice results in neuronal 
degeneration in regions associated with astrocytic tau pathology (Forman et al., 2005), 
indicating astrocytic tau pathology may play a direct role in both astrocytic and neuronal cell 
death (Kahlson and Colodner, 2015).
Although several tauopathies contain astrocytic tau pathology, evidence suggests that 
astrocytes do not phagocytise pathologic tau species. In the tauopathies, AD and FTD, tau 
oligomers are found to be surrounded by active astrocytes, but are not co-localized with 
astrocytes, suggesting the occurrence of an inflammatory response, but that astrocytes do not 
internalize tau oligomers (Nilson et al., 2016). Conversely, in AD, FTD, and transgenic mice 
overexpressing human tau (hTau), tau oligomers are found co-localized with active 
microglia, suggesting active phagocytosis of tau oligomers by microglia (Nilson et al., 
2016). In fact, microglia themselves have been implicated in the anatomic spread of tau 
pathology (Nilson et al., 2016). As shown in Figure 8, microglia are capable of both 
phagocytosis and exocytosis; therefore, microglial-dependent propagation of tau through 
phagocytosis and exocytosis may explain non-synaptic spread of tau throughout the brain 
(Asai et al., 2015). The depletion of microglia has been shown to reduce the propagation of 
tau in-vivo, both in an adenovirus model of rapid tau propagation and in transgenic mice 
overexpressing human mutant tau, P301S (Asai et al., 2015). Furthermore, transplanting 
microglia obtained from the brains of transgenic mice overexpressing human tau (hTau) and 
null for the microglial receptor, CX3R1, to the brains of wild-type mice results in increases 
in phosphorylated tau within the wild-type brains (Maphis et al., 2015b).
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The neuronal-microglial chemokine-chemokine receptor signaling pathway, CX3CL1-
CX3CR1 has been implicated in both neurodegeneration and neuroprotection following 
CNS injury (Bhaskar et al., 2010). CX3CL1-CX3CR1 signaling is known to be altered 
following TBI (Poniatowski et al., 2016), and may play a role in the development of tau 
pathology. In fact, tau overexpression is capable of increasing CX3CL1 levels, whereas 
CXCR1 depletion is capable of enhancing microglial activation and tau pathology. 
Transgenic mice overexpressing human tau (hTau) show increased levels of the neuronally-
derived ligand, CX3CL1 (Bhaskar et al., 2010). Knocking out the microglial receptor, 
CXC3R1, in hTau mice results in increases in microglial activation which are correlated with 
cognitive impairment (Bhaskar et al., 2010; Maphis et al., 2015b) In fact, hTau/CX3R1-/- 
mice show earlier tau pathology than hTau/CX3R1+/+ mice (Maphis et al., 2015b).
Alteration in the CX3CLI-CX3CR1 signaling pathway has been shown to enhance tau 
phosphorylation upon systemic administration of lipopolysaccharide (LPS), a compound 
capable of activating microglia through the TLR4 receptor (Bhaskar et al., 2010). LPS-
induced activation of microglia increases tau phosphorylation in wild-type and hTau mice 
(Bhaskar et al., 2010). However, the effect is enhanced in CX3R1-/- mice, further enhanced 
in hTau/CX3R1-/- mice, and is dependent on neuronal activation of the tau kinase, p38 
MAPK, and release of the microglial derived cytokine, IL-1β (Bhaskar et al., 2010).
In hTau/CX3R1-/- mice, microglial activation occurs prior to the appearance of tau 
pathology and correlates with its anatomic spread (Maphis et al., 2015b), suggesting that 
microglia activation enhances formation of pathologic tau. Additionally, studies suggest that 
microglial-induced neural toxicity is dependent on the presence of tau. Culturing neurons 
with LPS-activated CX3R1-/- microglia results in increased neurodegeneration; however this 
effect is attenuated in tau-/- neurons (Maphis et al., 2015a). Similarly, LPS activation of 
microglia in CX3R1-/- mice results in caspase-3 activation which is localized to p-tau 
positive neurons of the dentate gyrus, an effect which is attenuated in tau-/- mice (Maphis et 
al., 2015a). In non LPS-stimulated CX3R1-/- mice, a reduction in microglial activation and 
neuronal caspase-3 is also seen in tau-/- mice compared to tau+/+ mice (Maphis et al., 
2015a), an effect which correlates with attenuation of behavioral impairment (Maphis et al., 
2015a).
In addition to the CX3CLI-CX3CR1 signaling studies, several additional lines of evidence 
suggest that activation of microglia, as well as secretion of pro-inflammatory cytokines 
contribute to tau pathology. In fact, in the tauopathy AD, microglial expression of IL-1β is 
correlated with neuronal tau hyperphosphorylation (Sheng et al., 2001). In-vitro, activation 
of microglia with LPS results in microglial secretion of IL-β, neuronal activation of the tau 
kinase, p38 MAPK, increases in neuronal tau phosphorylation, and decreases in the synaptic 
protein, synaptophysin (Li et al., 2003). In primary hippocampal neurons, the pro-
inflammatory cytokine IL-6 has been shown to increase tau phosphorylation, an effect which 
is attenuated by inhibiting the tau kinase, cdk5 (Quintanilla et al., 2004). Additionally, 
exposing SY5Y or N-tera2 cells to media conditioned by LPS and IFNγ-activated human 
microglia results in increased production and release of tau (Lee et al., 2015). In fact, direct 
treatment of SY5Y or N-tera2 cells with the inflammatory cytokines, IL-1β or IL-6 was 
sufficient to increase levels of tau mRNA and protein expression (Lee et al., 2015).
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In-vivo, systemic administration of the microglial activator, LPS, results in increased tau 
phosphorylation acutely in the hippocampus of mice though activators of cdk5 and GSK-3β 
activation (Roe et al., 2011). In regards to cytokine expression, implantation of IL-1β beads 
into rat cerebral cortex, in simulation of chronic IL-1β exposure, results in increased mRNA 
expression of tau and p38 MAPK and increased tau phosphorylation (Sheng et al., 2001; 
Sheng et al., 2000). Similarly, adenovirus expression of the cytokine IFN-γ, a master 
regulator of inflammation, in two different mouse models of P301L tau overexpression 
results in increased phosphorylation of soluble tau through activation of the tau kinase, 
GSK-3β, however, INF-γ induction of tau phosphorylation did not result in increased tangle 
pathology or behavioral deficits (Li et al., 2015).
Although activation of microglia has been shown to increase tau phosphorylation, the ability 
of activated microglia to induce tau aggregation or tangle formation is less clear. For 
example, in rTg4510 mice overexpressing human mutant tau P301L, injection of LPS 
directly into the anterior cortex and hippocampus, results in ipsilateral and contralateral 
microglia activation and increases in tau phosphorylation one week following injection; 
however, pre-tangle and mature tangle formation was not increased (Lee et al., 2010). 
Interestingly, in this model activated microglia also did not co-localize with p-tau positive 
neurons (Lee et al., 2010). Conversely, in-vitro, activated microglia are capable of inducing 
tau aggregation through a mechanism involving production of ROS and the cytokine, TNF. 
Co-culturing primary hippocampal neurons with microglia pre-activated with LPS and IFN-
γ results in aggregation of tau in neurites as determined by FRET imaging, whereas tau 
aggregation is not seen in neurons cultured in the absence of activated microglia (Gorlovoy 
et al., 2009). Similarly, direct administration of the cytokine, TNF, to neuronal cultures 
results in formation of tau aggregates and increases in neuronal ROS production (Gorlovoy 
et al., 2009). In fact, TNF-induced tau aggregation is attenuated by the scavenging of ROS, 
suggesting that microglial-induced tau aggregation may be due to microglial secretion of 
TNF and activation of ROS generating neuronal NADPH oxidase (Gorlovoy et al., 2009).
In addition to activated microglia being shown to induce tau pathology, tau has been shown 
to activate microglia. In-vitro, transfection of microglia with Tau40, the longest isoform of 
human tau, results in increases in microglia activation, migration, phagocytosis, and 
cytokine secretion (Wang et al., 2013b). Additionally, in pure microglial cultures, Tau40 
induces accumulation of endogenous phosphorylated tau at the cell membrane, enhances 
secretion of non-phosphorylated tau, and alters expression of tau phosphatases and kinases 
(Wang et al., 2013b). In-vivo, overexpression of human mutant tau, P301L, results in 
increased expression of chemokines and innate immune system components (Li et al., 2015) 
and activated microglia accumulate near p-tau positive neurons (Sasaki et al., 2008). 
Similarly, in transgenic rats expressing truncated human tau, reactive microglia are 
associated with neurofibrillary tangles and axonal degeneration (Zilka et al., 2009b).
Upon further examination, many of the transgenic tau animal models suggest a cyclic 
relationship between microglial activation and formation of tau pathology. For example, the 
overexpression of human mutant tau, P301S, in mice is sufficient to increase microglial 
activation; however, microglial activation, synapse loss and impaired synaptic function all 
precede filamentous tau formation (Yoshiyama et al., 2007).
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It is currently unclear whether neuroinflammation in CTE and other tauopathies is 
detrimental or protective. In P301S mice, the immunosuppressant, FK506, is able to 
attenuate neuroinflammation, neurodegeneration and tau pathology (Yoshiyama et al., 2007). 
Similarly, minocycline, a tetracycline class antibiotic with neuroinflammatory properties, is 
able to reduce astrocyte activation, the production of inflammatory cytokines, and decrease 
tau phosphorylation in the cortex of transgenic mice overexpressing human tau (hTau) 
(Garwood et al., 2010). Importantly, both FK506 and minocycline have been shown to be 
neuroprotective in TBI (Miyauchi et al., 2013; Singleton et al., 2001; Vink and Nimmo, 
2009).
An additional pathway implicated in inflammation, the cholinergic pathway, is known to be 
impaired in TBI and neurodegenerative disease. In TBI there are deficits in cholinergic 
transmission and chronic loss of cholinergic neurons (Shin and Dixon, 2015), and recent 
evidence has demonstrated the occurrence of tau pathology in the cholinergic neurons of the 
nucleus basalis of Meynert in CTE brains (Mufson et al., 2016). The neurotransmitter, 
acetylcholine (Ach), is purported to have anti-inflammatory properties and the cholinergic 
pathway has been implicated in regulation of the immune system (Yoshiyama et al., 2012). 
In fact, chronic administration of a centrally acting anti-cholinergic to mice overexpressing 
human mutant tau, P301S, results in increases in tau phosphorylation and insolubility, 
activation of tau kinases, neurodegeneration, and microglial activation (Yoshiyama et al., 
2012). Furthermore, anti-cholinergic administration enhances the effects of LPS-induced 
microglial activation in P301S mice (Yoshiyama et al., 2012).
Therefore, if neuroinflammation is a detrimental process, acetylcholine esterase inhibitors 
(AChEI), which have long been used for symptomatic treatment of cognitive impairment in 
neurodegenerative tauopathies but are also purported to have anti-inflammatory properties 
due to their ability to upregulate cholinergic pathways (Yoshiyama et al., 2010), should be 
neuroprotective in animal models of tauopathy. If fact, in transgenic mice overexpressing 
human mutant tau, P301S, chronic treatment with the AChEI, donepezil, results in decreased 
astrocyte and microglial activation, decreased tau phosphorylation and insolubility, and 
decreased synaptic and neuronal loss (Yoshiyama et al., 2010). Furthermore, in P301S mice, 
donepezil is able to attenuate LPS-induced microglial activation and reduce brain levels of 
IL-1β and COX-2, suggesting that the neuroprotective effects of AChEI are due to 
attenuation of neuroinflammation. (Yoshiyama et al., 2010).
Although inhibition of neuroinflammation has been shown to be protective in some 
tauopathy models, neuroinflammation may also serve a protective role against the 
development of tau pathology and cognitive dysfunction through promotion of cellular and 
debris clearance mechanisms. For example, in transgenic mice overexpressing human 
mutant tau, P301S, LPS-induced activation of microglial also been shown to decrease 
phosphorylated tau and improve cognitive function through the promotion of authophagy 
(Qin et al., 2016).
Microglia themselves are also responsible for the clearance of damaged neurons, aberrant 
synapses and demyelinated axons (Sanchez-Mejias et al., 2016). Therefore, degeneration of 
microglia leads to neuronal degeneration in areas absent immune surveillance (Sanchez-
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Mejias et al., 2016). In the temporal cortex of the tauopathy, AD, dystrophic (degenerating, 
fragmented, senescent, etc.) microglia are co-localized with degenerating neurons positive 
for tau (Streit et al., 2009). Similarly, degenerating microglia are found in the hippocampus 
of AD, a region in which phosphorylated tau preferentially accumulates over Aβ plaques 
(Sanchez-Mejias et al., 2016). Although the appearance of dystrophic microglia, a 
phenomenon known to increase with aging, precedes the spreading of tau pathology in AD, 
suggesting that loss of microglial neuroprotection as one ages can lead to neurodegeneration 
(Streit et al., 2009), additional evidence suggests that soluble phosphorylated tau is capable 
of inducing microglial degeneration. For example, in-vitro, both phagocytosis of 
extracellular soluble p-tau and phagocytosis of apoptotic SY5Y cells containing intracellular 
soluble p-tau induces microglial toxicity, an effect which can be attenuated by immuno-
depletion of p-tau (Sanchez-Mejias et al., 2016).
In summary, CTE and TBI share common neuroinflammatory processes such as astrogliosis 
and activation of microglia. In fact, chronic neuroinflammation occurs in tauopathies and 
TBI. In CTE, tau positive astrocytes have been hypothesized to have several detrimental 
consequences, including blood-brain barrier dysfunction, extracellular glutamate 
dysregulation, and induction of neurodegeneration. In addition to astrocytes, the activation 
of microglia and the release of inflammatory cytokines have been implicated in induction of 
tau pathology and neurodegeneration. However, pathologic tau, itself, is capable of inducing 
both activation and degeneration of microglia, with degeneration of microglia capable of 
inducing neurodegeneration. Therefore, it is possible that following an initial insult capable 
of activating microglia and inducing pathologic tau formation, such as TBI, that microglia 
and tau interact to induce a feedforward cycle of neuroinflammation, pathologic tau 
formation, and neurodegeneration (Figure 8). In fact, chronic neuroinflammation is found 
both in tauopathies and decades following TBI.
5. Tau - A Biomarker for TBI
Stretching, shearing and degeneration of axons following TBI causes tau to be released from 
microtubules, increasing the levels of tau in biofluids. For this reason, there is growing 
interest in using cerebral spinal fluid (CSF), plasma, or serum tau as a biomarker for TBI, 
including mild TBI and sports-related head injury (Kulbe and Geddes, 2015). Furthermore, 
CSF tau already holds diagnostic potential in the tauopathy, AD (Blennow et al., 2010).
Increased levels of serum tau have been found in various models of animal TBI. For 
example, on the severe end of the spectrum, the cleaved form of tau (c-tau) is acutely 
elevated 6h post-injury in the serum of rats receiving a severe CCI. However, tissue levels of 
c-tau remained elevated beyond 6h and were significantly increased for at least 7 days post-
injury, both in the hippocampus and the cortex (Gabbita et al., 2005).
More diffuse models of injury, such as mild blast TBI, mild rotational TBI and repetitive 
closed head injury have shown post-injury increases in serum tau to be sustained for longer 
periods of time. Following a single, low-intensity blast TBI in mice, serum tau is 
significantly elevated two hours and one day following injury (Ahmed et al., 2015). 
However, non-significant elevations in serum tau were sustained for at least one month 
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following injury (Ahmed et al., 2015); a time course which parallels findings in mice 
receiving a mild blast-injury in which phosphorylated and cleaved forms of neuronal tau 
were increased 24h and one month post-injury (Huber et al., 2013). Therefore, increases in 
serum tau following blast TBI are likely to be representative of pathophysiological changes 
to tau in the brain tissue. Additionally, in rats receiving a mild TBI produced by rotational 
acceleration forces, serum tau is significantly elevated for at least 14d post-injury (Rostami 
et al., 2012), and in mice receiving repetitive closed head injuries, serum levels of total tau 
and phosphorylated tau are significantly elevated one day to one month post-injury, findings 
which again parallel increases in cortical phosphorylated tau (Yang et al., 2015).
In human TBI, increases in serum tau correlate with injury severity (Wang et al., 2016) and 
peak two days post-injury (Wang et al., 2016). However, in severe TBI, levels of CSF tau 
continue to rise beyond two days, peaking between five and 15 days post-injury (Franz et al., 
2003). In addition to full-length tau, cleaved tau isoforms have also been found in CSF 
following severe TBI (Zemlan et al., 2002; Zemlan et al., 1999). Importantly, several studies 
show that following severe TBI, levels of tau in the serum, cerebrospinal fluid, and brain 
extracellular fluid correlate with outcomes up to one year post-injury (Liliang et al., 2010; 
Magnoni et al., 2012; Ost et al., 2006; Wang et al., 2016; Zemlan et al., 2002), suggesting 
that in severe TBI, acute increases in peripheral tau may be related to pathologic processes 
that contribute to mortality and morbidity.
The ability of tau to serve as a biomarker for mild TBI in human patients is less clear. 
Although serum tau is known to be elevated following pediatric mild TBI (Guzel et al., 
2010), the clinical utility of serum tau as a biomarker for mild TBI has been questioned. For 
example, serum tau is unable to distinguish between mild TBI with or without intracranial 
lesion (Guzel et al., 2010; Kavalci et al., 2007), and serum levels of c-tau are unable to 
predict the development of post-concussive symptoms following mild TBI (Bazarian et al., 
2006; Ma et al., 2008).
Despite the less than promising results in regard to the value of peripheral tau as a biomarker 
for mild TBI, various tau isoforms have been found to be elevated in the plasma, serum, or 
CSF of groups at risk for sustaining multiple head injuries, such as athletes and military 
personnel. In fact, in male athletes, participation in collision sports is associated with 
elevated levels of plasma tau (Di Battista et al., 2016). In boxing, total tau levels are 
increased in the CSF for up to ten days and in the plasma for up to six days following a 
match, with significantly increased levels being seen in the CSF of players sustaining more 
hits to the head (Neselius et al., 2012; Neselius et al., 2013; Zetterberg et al., 2006). In 
hockey, total tau is elevated in the serum of concussed players for up to six days following 
injury and correlates with duration of post-concussive symptoms (Shahim et al., 2014). 
Similarly, caspase cleaved tau (c-tau), a fragment itself capable of perpetuating tau 
pathology, is elevated in the serum of hockey players post-concussion, and the tau fragment, 
Tau-A, correlates with the number of days it takes concussed players to return to play 
(Shahim et al., 2016). Tau-A is generated by cleavage of tau by ADAM-10 (Shahim et al., 
2016), a metalloproteinase which has been shown to be elevated in animal models of TBI 
(Warren et al., 2012).
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In addition to acute and sub-chronic time points, increases in peripheral tau have been shown 
to be sustained chronically in both athletes and military personnel. Compared to controls, the 
serum of symptomatic retired NFL players contains a significantly increased number of tau 
positive exosomes, which correlate with cognitive impairment (Stern et al., 2016). Exosomes 
are stable cell exocytosed nanovesicles, the content of which is representative of the cell of 
origin (Stern et al., 2016). Furthermore, plasma levels of total tau are significantly increased 
in military personnel sustaining three or more TBIs and levels correlate with post-concussive 
symptoms, despite the majority of participants having sustained TBIs at least 18 months 
prior (Olivera et al., 2015).
Therefore, these studies suggest that in addition to severe TBI, concussions, sub-concussive 
hits, and repetitive mild head injuries are sufficient enough to cause acute dissociations of 
tau from the microtubules, and that repeat injuries can lead to sustained increases in 
peripheral tau. Furthermore, the correlation that tau positive exosomes and sustained plasma 
tau levels have with chronic symptoms suggests that increases in peripheral tau may indeed 
be representative of brain pathology.
6. TBI, Tau, and CTE - The Animal Models
6.1 Experimental TBI-induced Tau pathology
Animal models have been used extensively to model TBI and are able to recapitulate several 
aspects of human TBI neuropathology and behavioral impairment (Xiong et al., 2013). 
Currently, animal models are being used to elucidate the effects of single or repetitive TBI 
on acute and chronic tau pathology. Ojo et al. (Ojo et al., 2016) has extensively covered 
methodologies, pathologies, and the benefits and challenges of using animals to study 
repetitive TBI and CTE. A multitude of factors are purported to influence CTE development 
including injury type, injury severity, impact number, impact frequency, age at injury, time 
elapsed since injury, genetics, gender, and environment (Ojo et al., 2016). Therefore, 
examining the relationship between TBI and CTE in animals is challenging; a difficulty 
which is evidenced throughout the literature. For example, while some animal models of 
repetitive TBI induce significant increases in tau phosphorylation, others have either found 
no significant tau pathology or tau pathology in only single animals (Ojo et al., 2016). 
Furthermore, despite increases in phosphorylated and total tau following injury, most studies 
fail to recapitulate other pathologic characteristic of CTE such as tangle formation, glial tau, 
perivascular tau deposition, and deposition of tau at the depths of sulci, a characteristic 
which would be practically impossible to model in the lissencephalic rodent brain (Ojo et 
al., 2016).
The anatomic and physiologic differences between humans and rodents (mice being the 
most common animal used in studies of tau) further complicate matters. Anatomically, 
human brains contain higher ratios of white to grey matter, higher ratios of glia to neurons, 
sulci, gyri, longer myelinated axons, and a denser vascular supply (Ojo et al., 2016). The 
ratio of 3R to 4R tau also differs in rodents and in humans. Healthy adult brains express 
equal ratios of 3R and 4R tau (Goedert and Jakes, 1990; Ojo et al., 2016), whereas rats and 
mice express 4R tau, an isoform which is preferentially phosphorylated and prone to 
aggregation, to a much higher degree than 3R tau (Hanes et al., 2009; McMillan et al., 2008; 
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Ojo et al., 2016). Additionally, animal models of CTE often depend on the use of transgenic 
mice. For example, many of the transgenic mice used to study pathologic tau utilize FTD-17 
mutations, such as P301L, which preferentially favor 4R splicing (Ojo et al., 2013; Ojo et 
al., 2016). Transgenic tau mice also overexpress tau compared to wild type mice, and are 
predisposed to the development of tau pathology (Ojo et al., 2016). In fact, in some CTE 
studies, transgenic tau mice are aged and already display tau pathology prior to injury (Ojo 
et al., 2013; Ojo et al., 2016).
Despite the difficulty in using animals to investigate the relationship between TBI, tau and 
CTE, important observations have been made. Several pathologic tau isoforms have been 
observed in experimental animal models of TBI, including increases in total tau, 
phosphorylated tau, cleaved tau, tau oligomers, tau aggregates and other pathologic tau 
confirmations. However, animal models of TBI are diverse, ranging from mild to severe, 
focal to diffuse, and single to repetitive, which can affect the time course and type of tau 
pathology seen following injury.
Several different models of TBI, including controlled cortical impact injury (CCI), fluid 
percussion injury (FPI), and blast injury have shown tau to be increased acutely following 
injury. CCI, a focal model of injury which includes aspects of contusion, hemorrhage and 
diffuse injury (Hall et al., 2005), results in severity-dependent increases in cleaved tau (c-
tau), with severe injury inducing significant increases in c-tau beginning at 6h in the cortex 
and 48h in the hippocampus, increases which are sustained for at least seven days following 
injury and which are attenuated by the neuroprotective drug CsA (Gabbita et al., 2005). 
Similarly, following a moderate FPI, a mixed model of focal and diffuse injury (Thompson 
et al., 2005), oligomeric and phosphorylated tau are increased acutely: 4h, 24h and 2 weeks 
post-injury (Gerson et al., 2016; Hawkins et al., 2013). Mild blast TBI, which encompasses 
both the blast wave and rotational acceleration-deceleration forces and results in diffuse 
injury, transient axonal injury, and vascular pathology (Courtney and Courtney, 2015; 
Kovacs et al., 2014), has also been shown to increase tau acutely following injury. For 
example, mild blast TBI increases phosphorylated tau in rat hippocampus 6h post-injury 
(Perez-Polo et al., 2015), and a repetitive blast injury consisting of three closely spaced 
blasts results in total tau levels being increased 24h post-injury in mouse cerebellum (Arun 
et al., 2013).
Chronic tau pathology has also been observed following blast injury. Tau phosphorylation 
and pathologic tau conformations are increased in rat hippocampus and cortex one month 
following either a single blast or six blasts spaced 48h apart (Turner et al., 2015). 
Furthermore, rats exposed to repeat injury showed evidence of perivascular tau pathology, a 
defining feature of human CTE (Turner et al., 2015). Seventy days following a single blast 
injury in rats, total tau protein is also increased in several brain regions including the 
amygdala, prefrontal cortex and hippocampus; an affect which can be attenuated by 
environmental enrichment (Kovesdi et al., 2011). Tau oligomers have also been observed to 
develop one month following a single blast TBI (Gerson et al., 2016). In fact, tau oligomers 
extracted from rat brains one month following a single blast TBI have prion-like 
characteristics, increasing the spread of tau pathology and accelerating the rate of cognitive 
decline when injected into brains of transgenic mice overexpressing human tau (Gerson et 
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al., 2016). Tau aggregation also occurs following blast TBI, although in a delayed manner. 
For example, three months following a single blast injury, rats develop tau aggregates in the 
prefrontal cortex and hippocampus that were not yet present one-month following injury 
(Sajja et al., 2015).
Chronic tau pathology has also been detected following closed head injury, another animal 
model of diffuse TBI. Similar to blast injury, increases in tau phosphorylation and 
pathologic tau conformations have been found one month following a single closed head 
injury (Turner et al., 2015). However, other studies have shown a requirement for repeat 
injuries in order to induce tau pathology following closed head injury. For example, in aged, 
transgenic mice overexpressing human tau and who already showed signs of tau pathology 
prior to injury, repeat injury (five injuries space 48h apart) but not single injury, resulted in 
increases in cortical and hippocampal tau phosphorylation three weeks post-injury (Ojo et 
al., 2013); however, other characteristic CTE pathologies, such as perivascular tau, neuritic 
threads and astrocytic tangles, were not seen (Ojo et al., 2013). Similar increases in tau 
phosphorylation following repetitive closed head injury occur in wild-type mice. For 
example, exposing mice to four closed head injuries spaced three days apart results in 
increased tau phosphorylation in the hippocampus and cortex, effects which are sustained 
for at least seven days and 30 days, respectively (Yang et al., 2015). Additionally, chronic 
increases in tau phosphorylation following repetitive closed head injury have been observed 
to occur beyond 30 days. For example, exposing mice to three closed head injuries spaced 
24h apart, results in increases in tau phosphorylation in the corpus callosum, cortex, 
hippocampus and amygdala six months following injury (Luo et al., 2014). Furthermore, 
evidence suggests that the presence of tau following repetitive closed head injury is linked to 
the development of pathology following injury. In fact, in a two-hit frontal impact model of 
closed head injury, knocking out tau attenuates chronic axonal degeneration and learning 
and memory deficits (Cheng et al., 2014).
Newer models of closed head injury, which also incorporate rotational acceleration-
deceleration forces in an attempt to more closely model human concussion, also have 
demonstrated increases in tau pathology following injury. In a model termed CHIMERA, 
which stands for Closed-Head Impact Model of Engineered Rotational Acceleration, an 
impact device is used to deliver a closed head injury to mice while allowing for free rotation 
of the head upon impact (Namjoshi et al., 2014). In CHIMERA, two impacts spaced 24h 
apart results in increases in tau phosphorylation over the first 48h following injury 
(Namjoshi et al., 2014). Chronic increases in tau phosphorylation have also been seen in 
similar models. For example, in another combined model of closed head injury and 
rotational acceleration, exposing mice to five injuries spaced 24h apart results in increases in 
tau phosphorylation for at least 30 days following injury (Kane et al., 2012). Similarly, in a 
closed head injury model which allows for head mobility and the use of non-anaesthetized 
mice, tau phosphorylation is increased in the cortex, hippocampus, amygdala and dentate 
gyrus seven days and one month following single or repetitive (42 injuries) injury (Petraglia 
et al., 2014). Furthermore, increases in tau phosphorylation were sustained out to six months 
in repetitive injury mice (Petraglia et al., 2014).
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Although less studied in isolation, evidence suggests that rotational acceleration-deceleration 
forces themselves are capable of inducing tau pathology. In fact, head restraint during blast 
injury is able to attenuate increases in tau phosphorylation, neuroinflammation, 
microvascular pathology, neurodegeneration, and learning and memory impairment 
(Goldstein et al., 2012). In swine models of rotational head injury, PHF-tau is reported to 
accumulate in neuronal perikarya following injury (Smith et al., 1999). Similarly, a model 
using air pressure to induce a rotational head injury in mice absent a blast wave, results in 
increases in tau phosphorylation two and eight weeks post-injury; however, similar to other 
models, additional aspects of tau pathology such as tau aggregation were not seen (Sabbagh 
et al., 2016).
6.1.1 Select Mechanisms of Experimental TBI-induced Tau Pathology—Multiple 
animal models of TBI, including diffuse injury, blast injury, closed head injury and 
rotational acceleration-deceleration injury, have all demonstrated increases in pathologic tau 
following injury. These models of injury also result in widespread damage to axons and 
white matter tracts, suggesting the possibility that diffuse axonal damage and pathologic tau 
formation are related. In fact, in transgenic mice expressing either human mutant tau, P301S, 
or the six isoforms of wild type human tau, a mild repetitive impact-acceleration injury 
induces dose-dependent advanced tau hyperphosphorylation and tangle formation ten weeks 
following injury (Xu et al., 2015). However, tau pathology only develops in regions of the 
brain associated with transient axonal injury; specifically, tau pathology develops in the 
retinal ganglion cells as this model induces transient axonal injury to the optic nerve (Xu et 
al., 2015). In addition to diffuse axonal injury being capable of inducing tau pathology, 
dendritic damage has also been implicated in increased tau phosphorylation. For example, in 
rats, epidural cortical compression rapidly results in mechanical disruption of the dendritic 
cytoskeleton, resulting in increases in phosphorylated tau, alterations in tau kinase and 
phosphatase activity levels, and dendritic remodeling, implying rapid changes to cortical 
circuitry that could have long lasting effects on brain function (Chen et al., 2010a).
Several experimental TBI studies have identified additional mechanisms which also may 
contribute to pathologic tau formation. Several studies have observed that increases in tau 
phosphorylation following injury are accompanied by alterations in phosphatase or kinase 
activity. In FPI, increases in tau phosphorylation twelve weeks post-injury are accompanied 
by decreases in expression and activity of the tau phosphatase, PP2A, neurodegeneration and 
cognitive impairment, effects which are attenuated by the administration of the PP2A 
activator, sodium selenite (Shultz et al., 2015). Similarly, in blast and weight-drop models of 
TBI, acute increases in tau phosphorylation coincide with decreases in activity of tissue non-
specific alkaline phosphatase (TNAP), a phosphatase with greater activity towards 
phosphorylated tau than PP2A (Arun et al., 2015). Additionally, following CCI in mice, 
increases in tau phosphorylation, cognitive impairment and hippocampal degeneration are all 
attenuated by administration of lithium, an inhibitor of the tau kinase, GSK-3β (Yu et al., 
2012).
In addition to alterations in tau phosphatase and kinase activity, oxidative stress also has 
been observed to coincide with tau pathology following experimental TBI. Exposing mice to 
a single blast results in increases in phosphorylated and cleaved tau 24h post-injury in the 
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cortex, hippocampus, and cerebellum, increases which are sustained in the hippocampus 30 
days post-injury, and which are accompanied acutely by increases in oxidative stress defense 
mechanisms in the hippocampus and cerebellum, namely increases in the mitochondrial 
anti-oxidant, SOD2 (Huber et al., 2013). Oxidative stress has also been seen to accompany 
tau pathology in repetitive models of TBI. In a repetitive blast injury model, exposing mice 
to six blasts spaced 48h apart results in increases in pathologic tau, apoptosis, and 
impulsivity, effects which are attenuated by administration of the antioxidant, lipoic acid 
(Lucke-Wold et al., 2015). Lipoic acid inhibits NOX4, an enzyme increased in CTE brains 
which is capable of inducing oxidative stress (Lucke-Wold et al., 2015). Additionally, in a 
repetitive mild closed head injury model, exposing mice to three impacts spaced 24h apart, 
results in increases in phosphorylated tau, inflammation, and synaptic and cognitive 
impairment 30 days post-injury, effects which are attenuated by inhibition of 
monoacylglycerol lipase (MAGL) (Zhang et al., 2015). MAGL metabolizes 
endocannabinoid 2-arachidonoylgylcerol (2-AG) to prostaglandins and arachidonic acid 
(Zhang et al., 2015). Therefore, inhibiting MAGL acts to increase 2-AG, a compound known 
for having anti-inflammatory and neuroprotective properties (Zhang et al., 2015), while also 
decreasing the 2-AG metabolite, arachidonic acid, which is itself capable of initiating LP 
(Bains and Hall, 2012; Hall et al., 2010).
Experimental TBI has also been shown to increase toxic forms of tau by impairing the 
function of the proline isomerase, Pin1. Pin1, converts tau phosphorylated at Thr231 from 
the cis isomer to the less toxic trans configuration (Kondo et al., 2015). Phosphorylation of 
Pin1 increases following experimental TBI, leading to decreased Pin1 activation and, 
therefore, increased levels of the cis isomer (Kondo et al., 2015). Pin1 can also be inhibited 
through cysteine oxidation (Chen et al., 2015), an event likely to occur under TBI-induced 
oxidative stress conditions. Formation of the cis isomer of phosphorylated tau (cis p-tau) is 
reported to be an early pathogenic event in the tauopathy, AD, (Nakamura et al., 2012), and 
increases in cis p-tau have been identified in CTE (Kondo et al., 2015), and in experimental 
models of severe TBI, repetitive mild TBI (rmTBI) and blast TBI (Kondo et al., 2015). In 
fact, six months following rmTBI cis p-tau which developed acutely at the site of injury has 
spread to additional brain regions (Kondo et al., 2015). Cis p-tau is suspected of being 
neurotoxic. In fact, in an experimental model of severe TBI, administration of a cis p-tau 
antibody prevents development and spread of cis p-tau, attenuates disruptions in microtubule 
and mitochondrial transport, and improves functional and behavioral outcomes (Kondo et 
al., 2015).
In addition to dysfunction of enzymes and oxidative stress pathways, dysfunctional tau 
clearance mechanisms have been observed following experimental TBI. A moderate-severe 
closed head injury in mice results in impairment to the glymphatic pathway for at least one 
month following injury and correlates with increases in tau phosphorylation (Iliff et al., 
2014). The glymphatic pathway is a perivascular network responsible for CSF recirculation 
and clearance of interstitial proteins such as tau and Aβ (Iliff et al., 2014; Iliff et al., 2012). 
The glympathic pathway is highly dependent on the protein, perivascular glial aquaporin-4 
(AQP4), which is also chronically impaired following experimental TBI (Iliff et al., 2014; 
Ren et al., 2013). In fact, knock-out of aquaporin-4 results in increases in tau 
phosphorylation, axonal degeneration, neuroinflammation, and behavioral deficits following 
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experimental TBI suggesting that chronic glymphatic dysfunction following TBI may 
contribute to the development of neurodegenerative tauopathies through impairment of tau 
clearance (Iliff et al., 2014).
6.2 Experimental TBI without Tau Pathology
Although multiple animal models have demonstrated that pathologic tau is increased 
following acute TBI, pathologic tau can be sustained chronically following TBI, and several 
possible mechanisms that could lead to tau dysfunction following injury, there have been 
other animal models which have failed to demonstrate any tau pathology following injury. In 
fact, even the use of transgenic mice does not always ensure formation of tau pathology 
following experimental TBI. For example, in a repetitive mild closed head injury in which 
aged transgenic mice expressing the shortest form of human tau (T44) received a total of 16 
injuries over the course of four weeks, only 1 in 9 mice developed neurofibrillary tangles 
and cerebral atrophy (Yoshiyama et al., 2005). However, except for the individual mouse 
displaying tau pathology, this model was also unable to induce any cognitive deficits six 
months post-injury (Yoshiyama et al., 2005).
Several additional examples demonstrate the difficulty of modeling CTE in rodents. In a 
mouse study that paralleled several clinical and pathological aspects of human TBI, a single 
mild closed head injury resulted in pathology and behavioral deficits that remained static 
over time, whereas repeat injury (five injuries spaced 48h apart) resulted in progressive 
neuroinflammation, white matter degradation, and behavioral impairment over 6-18 months 
following injury despite no increases in tau phosphorylation (Mouzon et al., 2014). 
Similarly, in a mouse model combining impact and rotational acceleration, repeating injuries 
on a daily or weekly basis resulted in increases in astrogliosis and cognitive impairment up 
to one year following injury, but no increases in tau phosphorylation (Mannix et al., 2013).
A lack of tau pathology following rmTBI has also been seen at more acute time points. For 
example, in a mouse model of repetitive mild closed head injury, five impacts spaced 24h or 
48h apart results in motor and cognitive deficits, axonal degeneration and astrogliosis, 
particularly in the visual system, ten weeks following injury; however, increases in 
hyperphosphorylated tau were not seen (Bolton Hall et al., 2016). Similarly, although 
exposing mice to five injuries spaced 24h apart results in increased hemorrhagic lesions, 
diffuse axonal injury, neurodegeneration, and astrogliosis 24h post-injury compared to 
intervals spaced 48h apart, neither injury paradigm results in increased tau phosphorylation 
(Bolton and Saatman, 2014).
In summary, use of animal models to study CTE and the development of chronic tau 
pathology following experimental TBI is complicated by a multitude of factors including 
heterogeneity of human injury, heterogeneity of individuals, and anatomic and physiologic 
differences between humans and rodents. Although individual studies have failed to 
recapitulate all aspects of CTE pathology, numerous studies have confirmed the ability of 
experimental TBI to induce acute and chronic tau pathology, and the ability of repetitive 
injury to exacerbate that pathology. Furthermore, animal models have confirmed 
mechanisms suspected of contributing to tau pathology following injury such as tau kinase 
and phosphatase dysfunction and induction of oxidative stress pathways, and identified 
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additional mechanisms that possibly contribute to tau dysfunction following injury such as 
Pin1 inhibition and dysfunction of the glympathic pathway.
7. Conclusions and Possible Neuroprotective Strategies to Prevent or 
Interrupt the Progression of CTE
Traumatic brain injury results in a secondary injury cascade that includes processes such as 
calpain and caspase activation, mitochondrial and ER dysfunction, increases in oxidative 
stress including generation of peroxynitrite which trigger, lipid peroxidation and LP-derived 
breakdown products, most notably the neurotoxic aldehydes 4-HNE and acrolein, and 
neuroinflammation. While these post-TBI biochemical and cellular pathophysiological 
events begin within the first minutes, days and hours post-TBI, there is evidence that some 
of these events may persist into the chronic injury phase exerting negative effects on 
recovery months and perhaps years after the single of repetitive TBI episodes and 
contributing to age-related neurodegenerative diseases. Similar processes occur in 
neurodegenerative tauopathies and many have been shown to occur upstream, downstream, 
and in a circular cascade with tau dysfunction (Figure 9). A history of TBI, particularly 
repetitive, is a risk factor for both CTE and AD; therefore, it is possible that several of the 
above mentioned pathologies, which occur acutely following TBI, lead to chronic 
neurodegeneration and tau dysfunction. However, the apparent complexities of the 
mechanistic link between acute post-traumatic secondary injury processes and their 
contribution to chronic outcomes is yet to be un-raveled. Nevertheless, since CTE has only 
been documented in individuals with histories of repetitive, and perhaps even single, TBIs, it 
is entirely possible that early initiation of neuroprotective treatments that will effectively 
inhibit the acute, subacute and early chronic secondary injury phases will lessen the 
development of the tauopathy that is the key neuropathology seen in CTE. While a single 
neuroprotective approach might be able to significantly attenuate the progressive brain 
damage in CTE, since a variety of cellular dysfunctions can lead to tau dysfunction, which 
can in turn lead to several cellular dysfunctions, it is likely that a multi-mechanistic 
neuroprotective combinational approach to CTE prevention and interruption will be needed.
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Definitions
2-AG 2-arachidonoylglycerol
3-NT 3-nitrotyrosine
4-HNE 4-hydroxynonenal
Ach acetylcholine
AChEI acetylcholine esterase inhibitor
AD Alzheimer's disease
ADAM-10 A disintegrin and metalloproteinase domain-containing protein 10
ANT adenine nucleotide translocator
APP amyloid precursor protein
AQP4 aquaporin-4
CCI controlled cortical impact injury
CDK5 cyclin-dependent kinase 5
CHIMERA closed-head impact model of engineered rotational acceleration
COX cytochrome oxidase
CsA cyclosporine A
c-tau cleaved tau
CTE chronic traumatic encephalopathy
CX3CL1 C-X3-C motif ligand 1 / fractalkine
CX3CR1 CX3C chemokine receptor / fractalkine receptor
DRP1 dynamin-related protein
ERAD ER-associated degradation
ERK extracellular-regulated kinase
FPI fluid percussion injury
FRET fluorescence resonance energy transfer
FTD frontotemporal dementia
GSK-3β glycogen synthase kinase-3β
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hTau human tau
IFN interferon
IL interleukin
JNK c-Jun-terminal kinase
LP lipid peroxidation
LPS lipopolysaccharide
MAGL monoacylglycerol lipase
MAP microtubule-associated protein
MAPK mitogen-activated protein kinase
MAPT microtubule-associated protein tau
mPTP mitochondrial permeability transition pore
mtNOS mitochondrial nitric oxide synthase
NADPH nicotinamide adenine dinucleotide phosphate
NFT neurofibrillary tangle
NOX4 NADPH oxidase 4 gene
PHF paired helical filament
PIN1 peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
PN peroxynitrite
PP2A protein phosphatase 2
PSD-95 postsynaptic density 95
PSP progressive supranuclear palsy
p-tau phosphorylated tau
rmTBI repetitive mild TBI
RNS reactive nitrogen species
ROS reactive oxygen species
SOD2 mitochondrial superoxide dismutase 2, manganese-dependent superoxide 
dismutase
TNAP tissue non-specific alkaline phosphatase
TBI traumatic brain injury
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TDP-43 transactive response DNA-binding protein
TLR4 toll-like receptor 4
UPR unfolded protein response
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Highlights
• Chronic traumatic encephalopathy (CTE) is a recently described 
neurodegenerative tauopathy that is a chronic sequela of traumatic brain 
injury (TBI).
• CTE occurs predominantly after repeated episodes of mild TBI in athletes 
involved in contact sports or in military combatants exposed to single or 
repetitive explosive blast-injuries.
• This review discusses the possible involvement of the well characterized post-
TBI pathophysiological mechanisms in the pathogenesis of tau protein 
deposition that is distinctly characteristic of CTE.
• The analysis of the possible interactions of TBI secondary injury with CTE 
tauopathy has suggested several neuroprotective approaches that might serve, 
either singly or in combination, to limit the development of CTE.
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Figure 1. Interplay between TBI pathophysiology and mechanisms of pathologic tau formation 
demonstrating several cyclic relationships between the two
TBI induces traumatic axonal injury (TAI), neuroinflammation, increases in intracellular 
Ca++, shearing of blood vessels, and tau hyperphosphorylation. TAI causes microtubule 
detachment of tau and tau mislocalization. Ca++ uptake by the endoplasmic reticulum (ER) 
and mitochondria leads to organelle dysfunction, including increases in ROS, RNS, and 
peroxynitrite (PN), initiation of lipid peroxidation (LP), and 4-HNE and acrolein formation. 
Hemorrhage-derived Fe++ catalyzes formation of reactive species and LP. 4-HNE and 
acrolein bind mitochondrial proteins, exacerbating dysfunction and generation of reactive 
species. Dysfunctional mitochondria enhance ER dysfunction, release cytochrome c, which 
activates caspases, and extrude Ca++ into the cytosol, which activates calpain. Calpain 
cleaves cytoskeletal proteins (e.g. spectrin) resulting in cytoskeletal degradation. 
Neuroinflammation, ER dysfunction, ROS/RNS/PN, mitochondrial dysfunction, caspase/
calpain activation, and cytoskeletal degradation contribute to formation of pathologic tau 
(e.g. post-translational modification, conformational change, aggregation, etc.). In return, 
pathologic tau contributes to neuroinflammation, ER dysfunction, generation of 
ROS/RNS/PN, mitochondrial dysfunction, caspase activation and cytoskeletal degeneration.
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Figure 2. Select pathways demonstrating the role of oxidative stress in formation of tau 
pathology
TBI induces mitochondrial dysfunction, resulting in increased oxidative stress, which in 
turn, exacerbates mitochondrial dysfunction. Proteases downstream of mitochondrial 
dysfunction cleave tau, forming truncated tau (t-tau), which in turn, exacerbates 
mitochondrial dysfunction. Experimental tau overexpression induces mitochondrial and 
peroxisome dysfunction. Peroxisome dysfunction exacerbates oxidative stress and is 
enhanced by oxidative stress. Oxidative stress increases tau kinases activity (GSK-3β, JNK) 
and decreases tau phosphatase activity (PP2A), resulting in hyperphosphorylation of tau, 
which decreases tau binding of microtubules (red X), leading to tau aggregation, which is 
enhanced by oxidative stress itself.
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Figure 3. Mechanisms by which peroxynitrite leads to formation of tau pathology
TBI-induced mitochondrial dysfunction generates peroxynitrite (PN), which in turn, 
exacerbates mitochondrial dysfunction. PN nitrates or oxidizes tau forming 3,3′-dityrosine 
or disulfide crosslinks, respectively. Crosslinked tau induces tau oligomerization, 
aggregation and filament formation. Disulfide crosslinked tau also decreases microtubule 
assembly. PN increases the tau kinase, p38 MAPK. PN-derived NO•2 increases the tau 
kinase, GSK-3β, through nitration of the GSK-3β upstream regulator, p85. Increased tau 
kinase activity results tau hyperphosphorylation which decreases binding of tau to 
microtubules (red X). NO•2 directly nitrates tau at the 3 position of tyrosine, generating 
tau-3NT. Tau-NT has decreased microtubule binding properties (red X) and inhibits tubulin 
assembly. Tau-3NT is preferentially degraded by the proteasome, an organelle that's function 
is inhibited by PN, resulting in build-up and aggregation of tau-NT.
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Figure 4. The role of 4-hydroxynonenal (4-HNE) and acrolein (ACR) in formation of tau 
pathology
TBI induces lipid peroxidation (LP). Overexpression of P301L mutant also increases LP as 
measured by the LP-derived, malondialdeyde (MDA). LP results in the formation of the 
neurotoxic aldehydes, 4-HNE and ACR, which covalently bind proteins, including tau, 
causing protein dysfunction. ACR increases activity of the tau kinases, GSK-3β and p38 
MAPK, and 4-HNE-modified tau inhibits alkaline phosphatase, resulting in 
hyperphosphorylation of tau, 4-HNE modified-tau, and ACR modified-tau, which decreases 
binding of tau to the microtubules (red X), leading to conformational changes, aggregation, 
and filament formation. Paired helical tau filaments are extensively modified by 4-HNE and 
ACR.
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Figure 5. Mechanisms by which endoplasmic reticulum (ER) stress and dysfunction can lead to 
formation of tau pathology
Following TBI increases in intracellular Ca++, derived extracellularly or from dysfunctional 
mitochondria, induce ER stress. ER stress increases activity of the tau kinase, GSK-3β, 
resulting in tau hyperphosphorylation, which decreases binding of tau to microtubules (red 
X). ER stress results in the buildup of misfolded and unfolded proteins, including tau, both 
directly and through inhibition of ER-associated degradation (ERAD). Tau itself inhibits 
ERAD through associations with the ERAD heterocomplex. ERAD and buildup of 
misfolded and unfolded proteins activate the unfolded protein response (UPR), which in 
turn, activates ERAD. The UPR results in increases in tau phosphorylation, which in turn, 
activate the UPR. UPR activation increases neurotoxicity and behavioral impairment and 
decreases synthesis of proteins, including synaptic proteins. ER stress activates the protease, 
caspase-3, resulting in tau truncation (t-tau) and increased neurotoxicity. Alzheimer's 
disease-derived microsomes contain ER fragments and ribosomes which strongly associate 
with oligomeric tau, resulting in decreased RNA translation and decreased protein 
concentrations.
Kulbe and Hall Page 64
Prog Neurobiol. Author manuscript; available in PMC 2018 November 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Figure 6. The role of calpain in the formation of pathologic tau
TBI-induced increases in intracellular Ca++ derived extracellularly or from dysfunctional 
mitochondria and ER, activate the protease calpain. The endogenous calpain inhibitor, 
calpastatin, is decreased in tauopathies such as Alzheimer's disease. Calpain cleaves tau into 
35kD and 17kD fragments. The 17kD tau fragment forms prior to increases in tau 
phosphorylation and may directly enhance tau phosphorylation (dotted arrow). Calpain 
induces activation of the tau kinase, ERK, resulting in hyperphosphorylation of tau, which 
decreases binding of tau to microtubules. 17kD has a decreased affinity for microtubule 
binding (red X) and may be neurotoxic.
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Figure 7. Mechanisms in which caspases play a central role in the formation of pathologic tau
Following TBI, caspases are activated downstream of ER dysfunction and mitochondrial 
release of cytochrome c. Overexpression of P301L tau or 4R also induce caspases activation. 
Caspases, including caspase-3, cleave tau at Asp421, but N-terminal caspase-cleavage also 
occurs (NH-tau). Caspases-cleaved tau can further exacerbate mitochondrial and ER 
dysfunction. Asp421 is preferentially degraded by autophagy, therefore, impairment to 
autophagy results in accumulation of Asp421 tau. Asp 421 tau leads to enhanced tau 
polymerization and phosphorylation, resulting in decreased binding of tau to microtubules 
(red X) and increased aggregation and filament formation. Caspase activation and Asp421 
expression lead to apoptosis. Asp421 precedes cognitive impairment.
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Figure 8. Proposed role for microglia in the formation of pathologic tau
TBI and experimental tau overexpression activate microglia. Microglia can be activated 
through decreases in the microglia receptor, CX3CR1, and increases in the neuronally-
derived ligand, CX3CL1, which is elevated following TBI and experimental tau 
overexpression. Microglial secretion of IL-6 increases tau mRNA and protein expression. 
Microglial secretion of IL-1β and IL-6 increases tau kinase activity (p38 MAPK and cdk5), 
as does the presence of the cytokine IFN-γ (GSK-3β), resulting in tau hyperphosphorylation, 
which decreases binding of tau to microtubules (red X), and microglial phagocytosis of 
hyperphosphorylated tau. Microglia spread tau in a prion-like manner through phagocytosis 
and exocytosis. Hyperphosphorylated tau induces microglia degeneration, resulting in 
decreased immunosurveillance and increased neurodegeneration. The microglia-derived 
cytokine, TNF, activates NADPH Oxidase, increasing ROS and formation of tau aggregates. 
The presence of phosphorylated tau enhances the effect of activated microglia on 
neurodegeneration, caspase-3 activation, and behavioral impairment. Activated microglia 
induce autophagy, resulting in autophagic degradation of tau.
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Figure 9. Simplified schematic demonstrating proposed pathological mechanisms that can 
contribute to CTE development and pathologic mechanisms that can be exacerbated by CTE
Examples of pathologic tau include hyperphosphorylation, nitration, oxidation, aggregation, 
filament formation, etc. For simplicity, relationships between pathologic mechanisms are not 
included in this figure, but are detailed elsewhere (Fig 1– 8).
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